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ABSTRACT 
Pain is a widespread and growing health problem worldwide that exerts a considerable 
social and economic impact on both patients and healthcare systems and, therefore, on 
society in general. Although current treatment modalities include a wide variety of 
pharmacological and non-pharmacological approaches, due to the complexity of pain 
and individual differences in clinical response these options are not always effective in 
mitigating and relieving pain. In addition, some pain drugs such as non-steroidal anti-
inflammatory drugs (NSAIDs), local anesthetics and opioids show several unfavorable 
side effects. Therefore, current research advances in this medical field are based on the 
development of potential treatments to address many of the unmet needs and to 
overcome the existing limitations in pain management. Nanoparticle drug delivery 
systems present an exciting opportunity as alternative platforms to improve efficacy and 
safety of medications currently in use. Herein, we review a broad range of nanoparticle 
formulations (organic nanostructures and inorganic nanoparticles), which have been 
developed to encapsulate an array of painkillers, paying special attention to the key 
advantages that these systems offer, (compared to the use of the free drug), as well as to 
the more relevant results of preclinical studies in animal models. Additionally, we will 
briefly discuss the impact of some of these nanoformulations in clinical trials. 
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1. PAIN: DEFINITION AND TYPES 
The current established definition of pain, “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of 
such damage”, established by the Subcommittee on Taxonomy of the International 
Association for the Study of Pain in 1994, suggests the complexity of this 
phenomenon[1]. This definition implies that pain is a subjective experience and, 
therefore, each individual interprets it based on unique early life experiences related to 
injury, consequently yielding a high inter-individual variability in pain perception. Also, 
culture heritage, gender, ethnicity and environmental, genetic and personality-related 
factors play a substantial role in tolerance and response to pain. The integration of these 
psychological and social factors into clinical practice is not easy and these individual 
differences in pain sensitivity often hinder the correct diagnosis and proper treatment of 
pain, making it an enormous public health problem[2].   
In addition, over the years, the lack of recognition of this condition as a priority health 
problem has caused major deficits in understanding the mechanisms and management of 
pain and has impeded the development and implementation of new therapies. At 
present, great efforts are being made to change the paradigmatic view of pain, aiming to 
have it recognized as a unique medical disease instead of a symptom of disease[3].  
From a clinical perspective, the use of a classification system for pain could be helpful 
to give an initial approximation to guide assessment and proper diagnosis of those 
patients suffering pain as well as to select a suitable treatment. Generally, pain can be 
categorized according to specific characteristics (Figure 1A): anatomic location 
(muscles, viscera, joints, tendons, and bones), pain physiology (nociceptive, neuropathic 
and inflammatory), pain duration (acute, chronic and breakthrough pain), intensity 
(mild, moderate or severe) and etiology (malignant or non-malignant).  
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However, the pathophysiological classification of pain is one of the most used in the 
framework for clinical management of pain considering that treatment approaches for 
nociceptive, inflammatory or neuropathic pain are different (Figure 1B). 
Nociceptive pain is produced by the stimulation of the particular pain receptors called 
nociceptors, which are sensitive to potentially harmful stimuli. In that case, pain 
operates as an early-warning physiological protective system to avoid any contact with 
the noxious stimuli[4]. According to the location of activated nociceptors, nociceptive 
pain can be either somatic (superficial and deep) or visceral pain. Somatic nociceptive 
pain arises from injury into superficial or deep tissues. It is usually characterized by 
being well-defined, clearly located, constant or intermittent and normally movement 
dependent. However, visceral nociceptive pain, which is typically diffuse, difficult to 
localize, usually constant, and sometimes attributed to a far body part , is produced by 
the stimulation of nociceptors located in the internal organs or viscera. 
After an unavoidable injury to tissues or nerves, an inflammatory response is triggered 
by activation of the immune system to aid in the healing of the damaged region. The 
main objective of this process is the elimination of potential pathogens, the clearance of 
damaged tissue, the restoration of the homeostasis and the anatomic and physiologic re-
establishment of the affected area. In addition, as a consequence of this inflammatory 
response and the temporary sensitization of the nociceptive system, a situation of 
tenderness or pain hypersensitivity is created in the damaged area and non-swollen 
surrounding tissues, preventing additional damage and promoting the protection of the 
injured area. Thus, the abnormal sensory processing implies that any innocuous stimuli 
that would normally not produce pain may now do so and noxious stimuli may cause an 
increased pain response. This kind of pain, named inflammatory pain, is protective, 
adaptive and beneficial for a successful recovery. Generally, this pain disappears at the 
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same time the injury state is resolved. However, under certain physiological or 
pathophysiological circumstances, nociceptive signaling can operate abnormally, 
causing pain with no discernable protective or reparative role. In these cases, pain 
becomes persistent and can last for months or years, as long as inflammation 
continues[5]. 
Finally, neuropathic pain, which is generated by lesion or dysfunction of the nervous 
system, is a maladaptive and multifactorial pain. In 2008, the concept of neuropathic 
pain was redefined by a group of experts in the fields of neurology and pain as pain 
caused by a lesion or disease of the somatosensory system[6].  Although a clear 
distinction is not easy, there are two subtypes of this disorder, peripheral and central 
neuropathic pain. Neuropathic pain disorders have common clinical characteristics, and, 
are frequently described as burning or stabbing pain. Also, it is often associated with the 
appearance of symptoms, such as allodynia, hyperalgesia, dysesthesia (tingling and 
numbness) and lancinating pain. 
2. PREVALENCE OF PAIN 
The published data of several population-based surveys carried out in Europe and the 
U.S. showed large differences between pain prevalence rates, which could likely be 
attributed to differences in the selected methodology such as the definition of chronic 
pain, the pain scale included in the survey and the selection of surveyed subjects. Thus, 
although a general prevalence of moderate to severe chronic pain of 19 % in the adult 
population was estimated in a large-scale telephone survey carried out in Europe and 
Israel, large variations were observed between participant countries[7]. More recently, 
an age-standardized analysis of 18 surveys revealed that 37 % of surveyed people in 
developed countries and 41 % in developing countries reported suffering a chronic pain 
condition in the last 12 months. In this study,  considerable international modification in 
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chronic pain prevalence rates was also observed[8]. Published data about an internet-
based survey conducted in the U.S. were similar; showing that the overall crude point 
prevalence of pain lasting at least 6 months was 34.5 %[9]. Hence, these data provide 
evidence that although the prevalence rates may vary substantially between different 
geographic regions, chronic pain is a habitual condition in the general population 
worldwide. This high prevalence across the globe is one of the many reasons why pain 
should be conceptualized as a public health priority. Despite the substantial variation in 
the country-specific prevalence rates, several findings were consistent globally. For 
instance, the overall prevalence of chronic pain is consistently higher in females than 
males and increases with age. Although the reasons for the sex bias are still not clear, 
possible mechanisms underlying gender-related differences include biological and 
psychosocial factors[10]. And in spite of several population-based studies having 
documented that population ageing influences the prevalence of the chronic pain 
condition, to date, there is no consensus concerning the existing association between 
these two factors. Some studies reported that this relationship appears to be lineal; 
others indicated that it steadily rises with increasing age up to approximately 65 years 
and, then, it declines slowly in the older age-groups. Regarding the psychosocial or bio-
behavioral factors, a relevant connection between pain and mental illness has been 
observed in both developed and developing countries[10].  
3. PAIN-ASSOCIATED COSTS 
Pain is considered an important clinical and social problem worldwide, having a 
significant economic burden on patients and their relatives, health systems and society 
in general. In addition, the extended life expectancy, increased levels of obesity and the 
sedentary lifestyle are likely to cause an increase in the prevalence of this condition and, 
therefore, on the impact of chronic pain in society. Chronic pain affects the physical and 
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psychological health of the sufferers, reducing their quality of life and interfering on 
their daily activities, autonomy, employment and social and economic well-being. Thus, 
the economic costs of pain are generally evaluated at two levels: direct cost associated 
with physician's visits, diagnostics, treatments, hospitalizations and medications and 
indirect costs due to the increased probability of having to leave the labor market as a 
consequence of the scarce productivity and high rates of absenteeism found in patients. 
According to a study carried out in the U.S. in 2010, the pain cost at national level 
ranged from $560 to $635 billion annually[11]. The comparison of these data with those 
published by the National Institutes of Health (NIH) demonstrated that the economic 
impact of persistent pain exceeded the economic costs of the 6 most costly diagnosed 
diseases.  An economic analysis of costs attributable to chronic pain in various 
European countries indicated that direct healthcare costs and indirect costs reached 
billions annually as well, representing between 1.5 % and 3 % of the European gross 
domestic product[12]. The economic impact of chronic pain and related conditions in 
different European countries can vary substantially because those studies have been 
focused mainly on specific pain subgroups such as back pain, musculoskeletal disorders 
and others. For example, in Ireland, the published cost of chronic pain was estimated at 
5.34 € billion or 2.86% of Irish Gross Domestic Product per year in 2008[13]. While 
several other international studies determined that the socioeconomic impact of back 
pain exceeds 1.18 € billion in Belgium[14], 1.86 € billion in Sweden[15] and 48.9 € 
billion in Germany[16] annually. 
4. CURRENT STATUS OF PAIN TREATMENT  
There is a need to improve chronic pain management to improve clinical outcomes and 
to generate tangible savings in the economy of patient and in health-care systems in 
general.  
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The goal of pain management is to reduce sensitisation, decrease pain amplification and 
restore normal pain thresholds, relieving pain completely and improving the quality of 
life of those people living with distress associated to this condition. The first key step to 
plan effective and individualized pharmacologic therapy is an adequate and 
comprehensive clinical assessment, involving not only the search for the physical 
source of the pain but also the documentation of pain history and the screening for 
psychosocial comorbidities that could contribute to a more complex pain condition. 
However, the multifactorial and subjective nature of chronic pain makes a standardized 
evaluation difficult to produce. Therefore, clinicians should use a variety of screening 
and assessment tools to predict prognosis and to search for risk factors or morbidities. 
This kind of evaluation, usually based on the use of scales, would allow health care 
providers to integrate pain intensity, pain affect and pain-related disability and to assess 
a multitude of patient-specific factors with the goal of determining individualized 
treatment. In addition, a therapeutic plan must be multidisciplinary, not only aiming at 
pain relief but also solving psychosocial factors associated with the disease outcome[17] 
(Figure 2).  
A variety of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), local 
anesthetics, antiepileptic drugs, antidepressants, topical agents (capsaicin, doxepin, 
topical NSAIDs, anesthetic patch), skeletal muscle  relaxants, and opioids are currently 
available and their use individually or in combination seems to be effective in the 
treatment of chronic pain disorders[18]. Furthermore, the combination of 
pharmacotherapy with nonpharmacologic therapies can play a key role in mitigating 
pain. Nonpharmacologic strategies including interventional pain management, 
physiotherapy, and psychotherapy as well, pain rehabilitation can decrease fear, reduce 
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distress, pain and anxiety, minimize adverse effects and allow patients to have an active 
role in self-managing their symptoms[19]. 
However, current pain pharmacotherapies present dose-related adverse side effects and 
insufficient efficacy in several kinds of pain disorders[20]. For example, NSAIDs and 
steroids, amongst the most habitually prescribed drug groups, potentially present severe 
side effects in the gastrointestinal tract (ulcers, bleeding, myocardial infarction, stroke 
and infections)[21,22]. Regarding local anesthetics, some of them are linked with a 
short action period which is inadequate at the clinical level, being often necessary to 
administer them in combination with neural blockade enhancers. In addition, the use of 
potent local anesthetic drugs such as bupivacaine can involve serious side effects on the 
heart and peripheral blood vessels (cardiotoxicity) and on the central nervous system 
(neurotoxicity)[23]. Likewise, the widespread use of opioid therapy for patients 
suffering pain continues being a controversial issue due to the reduction of their 
analgesic efficacy through the course of treatment and their limited clinical utility as a 
consequence of induced side effects. Most commonly reported opioid-induced side 
effects happen at gastrointestinal, cutaneous , neurologic and autonomic  levels[24,25]. 
As a consequence, medication adherence is negatively affected, leading to 
discontinuation of the treatment and, so, non-effective pain control, inadequate relief 
and reduced responsiveness to the treatment. Also, unpleasant side effects can affect the 
quality of life of patients according to the willingness of these patients to adapt to a new 
lifestyle. Recently, the implementation of different approaches has been recommended 
to attempt to reduce the resulting side effects of conventional opioids both before and 
during opioid treatment in elderly patients[26]. Some of these strategies include dose 
reduction, opioid rotation, altering the route of opioid administration, and symptomatic 
management of adverse effects[26]. However, efforts to overcome these adverse effects 
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have met with limited success. In addition, several studies have associated high rates of 
opioid prescription with an increased risk of abuse, addition, overdose and death[27,28]. 
To date, treatment methods for chronic pain are limited and many patients continue to 
receive ineffective treatments. In 2010, the Institute of Medicine (IOM) on pain in the 
U.S. reported that the strategy to address this problem is based not only on the 
development of new drugs but also on educating health care specialists in the complex 
etiology, prevention, assessment, and safe and efficacious treatment of pain[29].  
Thus, the development of new treatments for chronic pain is a high-priority in the 
medical field.  
5. NANOPARTICLE-BASED FORMULATIONS IN PAIN TREATMENT 
Researchers have been focused on the manufacturing of both organic and inorganic 
nanoparticle formulations intended for the delivery of a variety of pain drugs including  
local anesthetics, NSAIDs or opioids (Figure 3). Herein, the current progress and 
challenges in synthesizing nanoparticulated drug delivery systems for pain management 
are reviewed. 
5.1. ORGANIC NANOPARTICLE FORMULATIONS 
Among all types of drug carriers, organic nanoparticle formulations, including 
liposomes, polymeric nanoparticles, niosomes, solid-lipid nanoparticles, dendrimers and 
polymeric micelles, are offering unique advantages for their applications in the 
nanoparticle-mediated drug delivery field. The design of nanoparticles, their 
physicochemical properties of bioavailability, biocompatibility and biodegradability as 
well as the ease of using them for drug encapsulation, the precise control of the drug 
release at the desired site and pharmacokinetic properties are important parameters 
which are going to dictate their therapeutic outcome. In this section, we will review 
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specific examples of applications of organic nanoparticles as drug delivery systems for 
pain relief. 
LIPIDS BASED SYSTEMS 
Vesicle based 
Among the numerous nanoparticle formulations employed, liposomes, spherical 
vesicles made up of one or more phospholipid bilayers, have been studied profoundly as 
suitable candidates for chronic pain treatment (Table 1). Several studies demonstrated 
prolonged duration of anesthetic effect of some of the most commonly used local 
anesthetic after their encapsulation into liposomes. Thus, different liposomal 
formulations encapsulating intermediate-duration local anesthetics (prilocaine, lidocaine 
or mepivacaine) increased the duration and the intensity of anesthetic effect compared 
to plain solutions of each of these three local anesthetics[30]. For example, the duration 
of infraorbital nerve blocking was significantly prolonged in rats using liposomal 
prilocaine in comparison to free prilocaine, demonstrating an example of their 
effectiveness as an alternative to replace the local anesthetics in clinical practice[31]. In 
a later study, physicochemical stability after a sterilization process and local toxicity of 
this liposomal formulation were evaluated as a previous step to consider its possible use 
in future clinical trials. Studied liposomal formulation did not cause inflammatory 
response on rat paws, corroborating their safety as long acting local anesthetic 
carrier[32]. A similar in vivo study also demonstrated that encapsulation of ropivacaine 
into unilamellar vesicles substantially improved the intensity of their anesthetic effect 
and, thereby, prolonged the duration of sciatic and infraorbital nerve blockades in mice 
and rats, respectively[33]. In addition, this ropivacaine liposomal formulation did not 
induce toxicity in vitro or in vivo, indicating that liposomes have a cellular protective 
effect avoiding the usual cytotoxic effects of plain ropivacaine. The evaluation of the 
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local toxicity of liposomal mepivacaine formulations administered intra-orally in rats 
showed similar results. The authors demonstrated that this oral injection did not evoke a 
greater inflammatory reaction than that produced by a 0.9 % NaCl solution[34]. Taking 
into account these results, it could be said that the development of sustained release 
liposomal formulations containing local anesthetics improves their bioavailability and, 
thereby, enhances their pharmacological actions and reduces the local and systemic 
toxicity of these drugs compared to in their free form, and as such they are gaining 
popularity as promising candidates to alleviate pain in the dentistry field. 
On the other hand, liposomes are already being used as carriers of NSAIDs, non-
specific inhibitors of the cycloxygenase pathway thus suppressing the generation of 
inflammation mediators such as prostaglandins. Encapsulation plays a pivotal role in 
improving the efficacy, safety and tolerability of these active molecules[35]. For 
example, the significantly greater antinociceptive response exhibited by diclofenac 
loaded liposomes with respect to the nonencapsulated form, has been attributed to an 
enhanced drug solubility and more effective delivery of the loaded diclofenac to the 
targeted area[36]. The evaluation of the antinociceptive activity of this liposomal 
diclofenac was carried out in Sprague Dawley rats and male Balb/C mice using well-
established nociceptive assay models half an hour after ingestion of the drug, exhibiting 
a significantly higher antinociceptive response, better inflammatory pain inhibition and 
a greater tolerance for mechanical and thermal hyperalgesia in comparison to the non-
encapsulated form of diclofenac. Elron-Gross et al.[37] reported high encapsulation 
efficiency of diclofenac in two different types of bioadhesive liposomes covered with 
either hyaluronan or collagen, reaching therapeutically-relevant doses (13 mg /ml drug). 
Both liposomal formulations behaved as controlled release diclofenac depots with half-
lives of biologically active ingredient in a period of few days. These liposomes had a 
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great affinity for specific sites binding to recognition sites and moleculesin CT-26 cell 
lines, resulting in an increased retention of the liposomes in the targeted area where 
diclofenac needed to exert its action. In a later study, the same authors demonstrated 
that drugs retained their biological activity after encapsulation in this novel drug-carrier 
formulation based on liposomes. These results were confirmed in a rat osteoarthritis 
model, demonstrating substantially reduced inflammation levels over time, in 
comparison to control animals after a single intra-articular injection[38]. Also, these 
authors carried out the co-encapsulation of sodium diclofenac and dexamethasone, a 
hydrophilic and a hydrophobic drug respectively, in the same liposome in an effective 
manner.  
Regarding dermal topical anesthetic agents, Paavola et al.[39] studied the sustained 
ibuprofen release and in vitro dural permeation of liposomal gels of ibuprofen, showing 
a prolonged release and a marked increment of dural ibuprofen permeation compared 
with the control gel formulations.  
The transdermal administration of conventional liposomes to provide successful 
delivery of drug molecules into systemic circulation is a controversial issue. Although 
some reports suggest that liposomes are suitable carriers for skin drug delivery, many 
studies have shown that these carriers are not very effective due to their limited ability 
to go across the stratum corneum before reaching their cellular target[40]. For this 
reason, efforts are being made to design a new generation of liposomes with increased 
elasticity and flexibility, with the intent of overcoming the existing drawbacks. For 
example, Duangjit et al.[41] compared the capability of ultradeformable, deformable 
and conventional liposomes to deliver meloxicam, demonstrating that the first two 
formulations were  the  most  efficient vehicles  for  transdermal  drug  delivery  of this 
NSAID. 
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Liposome encapsulation of opioids is one of the alternative approaches used in the field 
of pain management in order to avoid the serious central side effects of opioids. 
Significant differences in the encapsulation efficiency and in the release kinetics were 
observed when the most commonly used opioids (morphine, alfentanil, fentanyl, and 
sufentanil) were encapsulated into D-α-dipalmitoyl phosphatidylcholine multilamellar 
liposomes compared to the use of the drug in free form[42]. Similarly, a method based 
on the hydration-rehydration technique was used to efficiently encapsulate the agonist 
opioid drugs oxymorphone and hydromorphone into liposomes. When liposome-
encapsulated oxymorphone was administrated subcutaneously in a single dose in a 
neuropathic pain rat model, it prevented the development of thermal hyperalgesia for up 
to seven days[43]. Similar studies have shown prolonged analgesic effects of liposome-
encapsulated hydromorphone after subcutaneous administration in chronic constriction 
injury model rats. It is worth mentioning that the analgesic effectiveness took place at 
both a pre-emptive level as well as once the neuropathic pain had developed due to the 
ability of this novel formulation for reversing thermal hyperalgesia for an extended 
period of time compared to non-loaded hydromorphone[44]. 
Several ligands have been incorporated across the nanoparticle surfaces to increase their 
binding affinity to targeted sites. Thus, loperamide HCl loaded immunoliposomes 
conjugated with the anti-intercellular adhesion molecule-1, (ICAM-1), antibody were 
designed to provide prolonged analgesic and anti-inflammatory effects by delivering the 
encapsulated opioid directly at the site of inflammation[45]. After intravenous 
administration in rat models with chemically- induced inflammatory pain, these targeted 
nanoparticles exerted a localized response at the peripheral inflammatory site, 
improving the therapeutic potency of this pharmaceutical formulation. In a similar way, 
the RGD targeting peptide was incorporated to the surface of tramadol encapsulated 
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liposomes in an attempt to increase the permanence of this formulation at targeted cells, 
raising the overall effectiveness of the opioid drug. In fact, the intranasal administration 
of a liposome-containing aerosol resulted in a greater analgesic effect as well as in a 
slower therapeutic onset in comparison with the non-loaded drug formulation. Hoekman 
et al[46] hypothesized that RGD peptide anchored in the liposome surface may facilitate 
its binding to integrin proteins on olfactory epithelial cells, resulting in retention of 
fentanyl for an extended time period.  
More recently, new efforts directed toward the development of an external stimuli-
responsive liposomal drug delivery have been made with the objective of providing on 
demand adjustable control over drug release that allows patients to adjust the duration 
and intensity of local anesthesia in parts of the body where pain occurs according to 
patient’s needs. For instance, a proof of concept carried out by Rwei et al.[47] showed 
that a temporal control of sciatic nerve blockade could be achieved in response to near-
infrared light irradiation using phototriggerable liposomal nanoparticles containing 
tetrodotoxin (TTX). Only a mild inflammatory response was observed at the site of 
nanoparticle injection. Similarly, gold nanorods attached to temperature sensitive 
liposomes produced repeatable and adjustable on-demand anesthesia infiltration or 
sciatic nerve blockade with minimal toxicity upon NIR irradiation[48].  
In addition to the aforementioned systems, ethosomes are a new class of vesicular 
nanocarriers whose use has evolved as non-invasive drug delivery systems over the past 
several years (Table 2). Ethosomes, unilamellar or multilamellar vesicles made up  
mainly of phospholipids, ethanol as a permeation enhancer, and water, were developed 
in the late 90s to resolve the problems associated with the incapacity of liposomes to 
cross the intercellular channels of the stratum corneum, that act as a rate limiting factor 
during drug permeation. Ethanol aids in the fluidization of the intercellular lipids 
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through the stratum corneum. In addition, the development of these ethanol-based 
vesicular carriers for transdermal delivery has become an interesting research area 
because this route of administration has many advantages over others, including the 
avoidance of gastrointestinal tract problems and hepatic first pass effects as well as 
improvement in patient compliance. A few studies have evaluated the potential use of 
ethosomes to deliver different local anesthetics transdermally.  Different ethosomal 
formulations containing ropivacaine[49], lidocaine[50,51] or benzocaine[52] were 
synthetized and characterized in terms of particle size and superficial charge, 
morphology, encapsulation efficiency and vesicles stability with the objective to 
establish the most appropriate synthesis parameters in each case. In addition, different 
preclinical studies were employed in these research efforts to evaluate the potential of 
various local anesthetic loaded ethosomal formulations showing an enhanced 
penetration into the skin layers in all cases. The only histopathological study proved that 
ethosomal formulations significantly modified the structure of the stratum corneum, 
observing swelling and increment of total thickness[49]. 
Similarly, ethosomal formulations have been proposed as potentially useful carriers for 
transdermal delivery of NSAIDs such as ketoprofen and sodium diclofenac[53,54]. In 
this scenario, aceclofenac loaded ethosomes were prepared, optimized and characterized 
by measuring different physicochemical properties and entrapment efficiency, 
demonstrating that they offer more vesicle density, drug loading, and deformability 
index as compared with that of other elastic membrane-based vesicles[55]. It has also 
been proven that formulations and physicochemical properties (vesicle size, elasticity 
and zeta potential) of diclofenac loaded ethosomes play a considerable  role in the skin 
permeability enhancement and, thereby, in the therapeutic results[56]. 
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For ease of their application and storage stability, ethosomal systems have been 
successfully incorporated in proper carriers such as gels, achieving the required 
viscosity and bioadhesive properties for an efficient adhesion to the skin. Optimized 
formulations of ibuprofen, indomethacin, aceclofenac, lorxicam or piroxicam loaded 
ethosomal vesicles were dispersed in a gel using carbopol, one of the most commonly 
used gel-forming agents, achieving pharmaceutically acceptable formulations[57–61]. 
In general, in vivo pharmacodynamic studies of these nanoethosomal gels showed 
improved skin permeation and enhanced anti-inflammatory activity compared with 
control formulations. For example, a more effective anti-inflammatory activity was 
observed when meloxicam nanoethosomes added into carbopol-based gels were 
evaluated in a rat paw edema model induced by carrageenan [62]. Thus, the inhibition 
of swelling of the edema by this formulation was higher than that observed with oral 
administration of meloxicam. 
Particle based 
Solid lipid nanoparticles (SLNs) are nanocolloidal drug delivery systems that have 
emerged as alternative systems to the existing traditional carriers (i.e.,  polymeric 
nanoparticles, liposomes and others) to overcome limitations such as poor 
physicochemical stability and low encapsulation efficiency for hydrophobic drugs 
(Table 3). These nanosized particles, which have a solid lipid matrix made of 
physiologically well-tolerated, biocompatible, and biodegradable lipid components, 
present several benefits such as low acute and chronic toxicity, improved physical 
stability, low cost, free organic solvent synthesis, ease of scale-up and sterilization. 
Only a few studies have been published concerning the encapsulation of local 
anesthetics by SLNs. In one study, lidocaine loaded solid lipid nanoparticles prepared 
with solid lipids of different melting points were synthetized for the purpose of 
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prolonging the short duration of the epidural analgesia of this local anesthetic. Although 
all formulations showed a sustained release profile, which depended on the nature of the 
selected solid lipid, glyceryl palmitostearate-based SLNs demonstrated the longest 
extended-effect[63]. Although no sign of local anesthetic toxicity or irreversible 
functional impairment was observed, the authors pointed out that more extensive 
toxicity testing is required to establish the specific adverse effects, if any, of this 
investigational formulation. Some studies have also reported the incorporation of SLN 
dispersions into hydrogel-based formulations suitable for topical applications. For 
example, the intensity and duration of anesthesia using benzocaine significantly 
improved when benzocaine loaded SLN-based hydrogels were used compared to just 
benzocaine hydrogels[64]. SLN-based hydrogels with lidocaine were also prepared, 
characterized and successfully used in preclinical studies. As well, in vivo efficacy 
results of the nanoparticulate systems on guinea pigs showed a prolonged anesthetic 
effect with lidocaine loaded SLNs acting as depots from which the local anesthetic was 
slowly released [65]. 
Recently, a variety of topical systems based on SLNs has been used for administration 
of active substances and have shown success in preclinical studies. This method of 
administration is the most preferred route for management of ocular inflammations. In 
fact, ocular drug delivery has become a major challenge because most of the topical 
ophthalmic formulations commercially available reach the inner ocular tissues with 
difficulty and therefore are associated with poor bioavailability. NSAIDs such as 
indomethacin have been successfully incorporated in SLNs significantly improving 
ocular bioavailability possibly because of improved pre-corneal retention and enhanced 
drug corneal permeability[66]. Furthermore, a cationic polymer, chitosan, was used to 
coat the surface of indomethacin loaded SLNs to obtain an enhanced ocular penetration 
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of the encapsulated therapeutic agent and, thereby, higher drug levels in inner ocular 
tissues due to the adhesive properties of chitosan[67]. 
Regarding topical delivery to the skin, SLNs could be used as potential vehicles for 
prolonged and targeted delivery and, therefore, successfully resolve the problems 
related to the systemic toxicity of these anti-inflammatory drugs. For example, an 
enhanced concentration of the naproxen remained retained locally in the skin, increasing 
the anti-inflammatory response of the encapsulated drug in an in vitro skin permeation 
study carried out with naproxen loaded SLNs[68]. Recently, Peng et al.[69] observed 
high encapsulation efficacy of piroxicam in SLNs accompanied by an in vitro sustained 
release of the entrapped drug compared to formulations containing the free NSAID. One 
of the strategies used to enhance drug delivery through skin is the introduction of 
structural modifications within the skin by adding chemical enhancers. Thus, these 
authors added oleic acid, a chemical permeation enhancer, to topically administrate 
piroxicam-SLNs solutions, achieving a substantial improvement in skin penetration. 
The anti-inflammatory response of different platforms was evaluated in a rat paw edema 
model induced by carrageenan. The highest inhibition rates were achieved when SLNs 
were used as carriers of piroxicam together with oleic acid as a permeation enhancer. 
However, similar results in reducing carrageenan-induced injuries were observed with 
piroxicam-SLNs with or without added oleic acid groups. Kaur et al.[70] recently 
evaluated the use of diflunisal loaded SLNs gel formulations for topical/dermal 
application. Ex vivo skin permeation/retention assays and preclinical investigations in 
various animal models for therapeutic efficacy evaluation revealed the potential of these 
formulations to effectively treat local inflammatory conditions associated with various 
pain disorders. Thus, better skin permeation and retention were observed in comparison 
to conventional cream formulations (oil-in-water (o/w) cream). Several mechanisms 
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have been used to explain the mode of action of these carriers. In general, SLNs 
promote skin permeation owing to their occlusive and adhesive properties. Thus, they 
adhere to the skin surface forming a hydrophobic monolayer that combines with the 
skin lipidic film, providing an occlusive effect. The formation of an occlusive layer 
reduces the loss of moisture, maintaining sufficient skin hydration which ultimately 
facilitates drug penetration into deeper layers of skin. In addition, SLNs may interact 
with lipids in the outermost skin layer, resulting in a modified stratum corneum 
morphology and increased drug penetration across the skin. On the other hand, good 
skin retention has been assigned to better contact of the incorporated drug with the 
outermost layer of the epidermis thanks to elevated surface area offered by the nano-
scaled SLNs.  
Similar results were observed after intra-articular administration of celecoxib loaded 
SLNs, exhibiting sustained release properties, enhanced retention of the NSAID in the 
joints and lower distribution in the reticuloendothelial organs than free celecoxib[71]. 
Regardless of the via of administration, the histopathological studies carried out in the 
above cited reports established the biosafety of SLN-based systems on mice skin and on 
rat joints, respectively[70,71]. 
The search of more efficient, safer and innovative opioid-based controlled release 
formulations has driven researchers towards the encapsulation of these chemicals in 
SLNs. In this context, a high entrapment rate of buprenorphine hydrochloride and its 
methylated prodrugs into SLNs was achieved by Wang et al.[72] The buprenorphine-
loaded SLN-based formulation presented a moderate release profile of the drug, 
prolonged antinociceptive effect, and reduced toxicity. Küchler et al.[73] developed 
morphine- loaded SLNs as a new and innovative approach to topically apply opioids 
and, thereby, to reduce pain in severe skin wounds. Although these authors described 
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the influence of the unloaded and morphine loaded nanoformulations in different 
processes of wound healing such as keratinocyte migration and re-epithelization, drug 
release profiles of morphine- loaded SLN was not reported. 
A second generation of lipid nanoparticles, called nanostructured lipid carriers (NLCs), 
has appeared in an attempt to overcome limitations of SLNs such as low drug payload 
capacity and risk of drug loss during the solidifying step of the synthesis process and 
upon storage[74] (Table 4). In fact, the encapsulation of benzocaine and lidocaine in 
NLC dispersions was evaluated by Puglia et al.[75], exhibiting better results in terms of 
encapsulation efficiencies for both local anesthetics than those formulations based only 
on SNLs. In addition, the authors corroborated the influence of the lipid phases of these 
nanoparticulated systems in the in vitro drug release rate, as previously described[76]. 
In this case, both the drug partition between oil compartments and solid lipid and a 
progressive interface between solid lipid and water seem to be responsible for a 
sustained drug release. These authors reported a prolonged antinociceptive effect 
achieved when lidocaine or benzocaine loaded NLCs were topically applied on the rat-
tail, most likely due to the creation of a depot  of  therapeutic agent into the upper skin 
layers.  
Ribeiro et al.[77] optimized a process for the synthesis of NLCs based on cetyl 
palmitate and capric/caprylic triglycerides for delivery of the local anesthetics lidocaine 
and prilocaine applied in dentistry. The optimal formulation, which was 
physicochemically stable during 14 months in storage at room temperature, presented 
desirable structure-dependent properties, high encapsulation efficiency of the eutectic 
mixture of both local anesthetics and satisfactory sustained release profile, confirming 
the potential of this formulation for use during and after the dental procedures.  
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As in other formulations, the objective of the encapsulation of NSAIDs in NLCs is to 
improve their pharmacokinetic and pharmacodynamic properties and avoid the adverse 
effects produced at the gastrointestinal level. For example, oxaprozin loaded NLCs 
functionalized with folic acid were designed to overcome the side effects that this 
NSAID produces when it is administrated orally [78]. Also, flurbiprofen or 
indomethacin- loaded NLCs [67,79] and flurbiprofen or lornoxicam loaded NLCs[80–
82] have been designed, optimized and proposed as delivery systems suitable for ocular 
and transdermal delivery, respectively. These topical formulations were used and were 
shown to enhance efficiency in in vitro or in preclinical studies. Similarly, in order to 
ameliorate the bioavailability of ocular medications, the viscosity and mucoadhesive 
properties of ibuprofen-loaded NCLs were modified by means of the combination of 
these lipid nanocarriers with the thermoresponsive polymer Pluronic F-127 to extend 
the precorneal residence time and to improve the drug availability. These new 
ophthalmic formulations based on NLCs, which turned into a gel at corporal 
temperature, presented high encapsulation efficiency and a prolonged ibuprofen release 
profile[83]. Although the data obtained in in vitro biocompatibility studies did not show 
cytotoxic effects of optimized formulations in Y-79 human retinoblastoma cells, the 
authors pointed out that others preclinical studies have to be carried out to corroborate 
the biosafety of the developed NLCs for ocular drug delivery.  
NSAID loaded NCL carriers have also been investigated for topical treatment of skin 
diseases. For example, celecoxib[84], meloxicam[85,86], indomethacin[87], 
ketoprophen and naproxen[88], and valdecoxib[89] have been incorporated into NCL-
based gels to improve current topical drug therapy. Once more, authors hypothesized 
that the small size and the high specific surface area of these nanocarriers ensure close 
contact with the stratum corneum, thus provoking a reduced burst drug release. Instead, 
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the formation of a drug depot using those vectors guarantees the increase in the 
residence time and the release of the active ingredient in a sustained mode toward 
deeper skin layers. Generally, this dermal location of the carriers allows for a skin 
targeting effect, reducing drug side effects by means of lower systemic uptake of the 
drug. In addition, it is worth mentioning that Khurana et al.[86] observed that the 
application of meloxicam-NLC gel induced a significant reduction of the total lipid 
content of the stratum corneum, leading to the disruption of the barrier properties and 
facilitating drug permeation into the skin. In addition, toxicity screening of meloxicam 
loaded NLC gel showed suitable skin tolerability and safety for transdermal delivery. 
In the only previous study concerning the encapsulation of opioids in NCLs, several 
lipid nanocarriers with different liquid oil/solid lipid ratios were used to encapsulate 
buprenorphine and its ester prodrugs (buprenorphine propionate, valerate and enanthate) 
with the main purpose of modifying its pharmacokinetics and, thereby, overcoming the 
current limitations of the clinical use of this drug for treating chronic pain[72]. In spite 
of having a moderate drug release profile among all tested carriers, loading 
buprenorphine propionate into NLCs prolonged the duration of the antinociceptive 
effect up to 10 hours, being the most potent carrier tested in this study. The utilization 
of the prodrug approach together with the design of delivery systems based on lipids 
seems to be a good strategy to achieve a prolonged efficacy of opioid agents. 
POLYMER BASED SYSTEMS 
Polymeric nanoparticles, composed of natural, semi-synthetic, and/or synthetic 
polymers, have been extensively studied as promising organic nanoparticle systems for 
pain treatment (Table 5). Major advances have been registered in the synthesis, 
formulation, processing, and characterization of new polymer-based nanoformulations 
to improve the therapeutic outcome of various pain killers. One of the current 
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approaches consists of the development of sustained delivery drug systems to provide 
long-lasting therapeutic alternatives with reduced toxicity. Biodegradable polymers 
such as polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA) and 
polycaprolactone (PCL) used in a multitude of FDA approved therapeutic devices have 
also been widely used to synthesize local anesthetics loaded nanoparticulated carriers, 
providing a base for future applications in pain management. In this regard, PLGA 
nanocarriers containing bupivacaine, ropivacaine or benzocaine [90–94], lidocaine 
encapsulated PCL nanospheres[95], and benzocaine- loaded PLA or PCL 
nanocapsules[96] have been proposed as interesting candidates to overcome the 
drawbacks of local anesthetic. De Mello et al.[94] pointed out the importance of the 
composition of the core not only in parameters such as toxicity, good physicochemical 
stability and others but also in boosting the efficiency of analgesia. In regard to sciatic 
nerve blockade by local anesthetics encapsulated in polymeric nanoparticles, similar 
findings have been reported in several studies, indicating that local anesthetic loaded 
formulations significantly enhanced the intensity and duration of analgesia in 
comparison to non-loaded drug[94,95,97].  
Both natural and synthetic polymers can be blended for developing new polymeric 
materials with improved physical and mechanical properties and biocompatibility in 
comparison with those made of just synthetic polymers. In order to improve the 
pharmacological properties of bupivacaine, alginate/bis(2-ethylhexyl) sulfosuccinate 
(AOT) and alginate/chitosan nanoparticles loading this local anesthetic were developed 
and characterized, obtaining a slower and sustained drug release profile in comparison 
with free bupivacaine. These potential pharmaceutical carriers, were physicochemically 
stable and presented a significantly reduced toxicity with respect to just 
bupivacaine[97]. In another similar study, two hydrophilic nanocarriers with different 
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structures, alginate/chitosan nanospheres and polietilenglicol (PEG)-PCL nanocapsules, 
were used to encapsulate arcaine, a dental, amide-type local anesthetic. Overall, higher 
encapsulation efficiency, a slower release profile, and a lower toxicity were observed in 
the case of PEG-PCL nanocapsules in comparison  to the other formulations and 
unloaded drug[98]. 
In relation to NSAIDs, numerous reports concerning the application of formulations 
based on polymers have been published: piroxicam-loaded nanoparticles consisting of 
PLGA and Eudragit® RL[99],  ibuprofen-loaded Eudragit® S100 nanoparticles[100], 
diclofenac sodium loaded Eudragit® L100 and Eudragit® L100-(PLGA) nanoparticles 
containing [101], celecoxib-loaded PCL-, PLA-, or PLGA-nanoparticles based topical 
ophthalmic formulations[102], N-trimethyl chitosan nanoparticles containing sodium 
diclofenac [103], meloxicam loaded PCL nanoparticles[104], ibuprofen-sodium loaded 
PEGylated gelatin nanoparticles[105], indomethacin- loaded Eudragit L 100 
nanocapsules[106], piroxicam-loaded ethyl cellulose-based nanoparticles[107],  and 
dexibuprofen- loaded PEGylated PLGA nanospheres[108] have been proposed as 
potential candidates to provide controlled  release  properties, enhancing the therapeutic 
efficacy of these drugs and reducing the  severity  of their gastrointestinal  side  effects.  
As mentioned in the liposomes section, recently, smart nanoparticles have been 
designed to react to external factors, such as pH, light, and temperature[109]. For 
instance, the release of the charged NSAIDs into indomethacin loaded smart 
nanoparticles based on pullulan-g-poly(N-isopropylacrylamide) (PNIPAM) and 
piroxicam-loaded polypyrrole nanoparticles was triggered by changes in 
temperature/pH and pH, respectively[110,111]. 
Several opioids have been encapsulated in polymer based pharmaceutical formulations 
with the purpose of protecting and delivering them at a desirable site, avoiding their 
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undesirable side-effects. For example, to facilitate the transport of nanoparticles 
containing molecules with therapeutic value through the blood-brain barrier, Lalani et 
al.[112] conjugated different ligands (transferrin and lactoferrin) to tramadol 
hydrochloride- loaded PLGA nanoparticles, achieving an enhanced brain uptake due to 
receptor mediated intracellular endocytosis. The most pronounced nociceptive effect 
was achieved after intravenous injection of tramadol-loaded PLGA nanoparticles 
surface modified with lactoferrin. Similarly, an efficient transport of loperamide to the 
central nervous system was achieved when loperamide- loaded PLGA nanoparticles 
were functionalized with an antibody against the transferring receptor, overexpressed in 
the blood-brain barrier[113]. Formulated nanoparticles crossed the blood-brain barrier 
and produce central analgesia at levels similar to those of the positive morphine control. 
The surface of the loperamide loaded-PLGA nanoparticles was also modified with octa-
arginine 8 (cell-penetrating peptide) to improve blood-brain barrier delivery[114]. In 
fact, a rapid nanoparticle uptake was observed in an in vitro blood-brain barrier cell 
model, probably due to specific receptor-mediated transport[114]. In addition, although 
R8-PLGA NPs administered intranasally as well as intravenously showed the highest 
rates and extent of loperamide delivery, the profile of antinociceptive effect was 
different over time in both cases. In the same way, Kreuter et al.[115] demonstrated that 
only dalargin preadsorbed to polysorbate 80 coated polybutylcyanoacrylate, (PBCA), 
nanoparticles was able to enter the brain to cause antinociceptive effects.  
The ability of chitosan nanoparticles to deliver the D-ala2-D-leu5-enkephalin synthetic 
opioid (DADLE) to neuronal cells in a sustained manner, protecting the loaded opioid 
from degradation and extending its analgesic response[116], was also reported. In 
addition, the encapsulation of tapentadol in stable polysorbate 80 coated chitosan 
nanoparticles has been proposed to prevent hepatic first pass metabolism, improving the 
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delivery of this opioid to the brain, and, thereby, improving its antinociceptive 
efficacy[117]. 
Nanogels, multifunctional polymer-based materials, are currently being explored as a 
strategy to create innovative targeted drug delivery systems. High drug encapsulation 
capacity, excellent thermodynamic stability, low viscosity, tunable size, ease of 
preparation and minimal toxicity are some of the potential advantages attributed to these 
hydrophilic three dimensional polymeric networks. For instance, a controlled release of 
piroxicam for more than 21 days was achieved when piroxicam-loaded polypyrrole 
nanoparticles were dispersed in a calcium alginate hydrogel, highlighting the 
importance of this extended delivery particularly for patients with chronic pain[110]. 
Hydrogels containing pranoprofen-loaded PLGA nanoparticles and chitosan–ibuprofen-
gellan ternary nanogels have been also proposed as novel formulations with potential 
topical application[118,119]. 
The same as with the previously described nanoparticulated vectors, in recent years, 
research has also focused on the synthesis of smart nanogels sensitive to subtle change 
by environmental stimuli like the pH or temperature[120]. As such, nanogels based on 
thermoresponsive polymers have been designed with the objective of obtaining on 
demand drug delivery. For example, acid-functionalized nanogels based on PNIPAM 
were loaded with effectively high amounts of bupivacaine principally owing to the ionic 
interactions that take place between the anionic charges of the nanogels and cationic 
nature of this local anesthetic at physiological pH[121]. Regarding in vitro cytotoxicity 
assays and in vivo biocompatibility studies, nanogels exhibited minimal cytotoxic 
effects in a wide range of concentrations over several cell lines and, in general, they 
showed proper biocompatibility after peritoneal administration in model animals. Also, 
biodegradable nanoparticles in hydrogels were specifically used for encapsulating 
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lidocaine and prolonging infiltration anaesthesia without causing severe toxicity[122]. 
Foley et al.[123] synthetized ropivacaine-chitosan thermogel-based controlled release 
systems (with and without dexamethasone) to minimize the toxicity of the local 
anesthetic without loss of anesthetic effectiveness. The gel formulation made up of 
chitosan, ropivacaine and dexamethasone prolonged neural blockade activity in 
comparison with its counterparts after directly applying it on the sciatic nerve. Also, an 
inflammatory effect associated with the treatment was observed in all cases except for 
in the case of thermogels containing dexamethasone and having a low ropivacaine 
concentration (75 mg/Kg), postulating that the inflammation is likely an effect 
dependent of the dose of this local anesthetic. It is worth mentioning that adding 
dexamethasone to thermogels was able to ameliorate the observed inflammatory 
response[123]. Finally, a sustained release profile and a prolonged ocular residence time 
of ketorolac were obtained with a thermosensitive gel including ketorolac tromethamine 
loaded Eudragit® RL100 nanodispersions, improving the ocular availability of this 
NSAIDs in targeting without causing irritation to eye[124]. 
Dendrimers, are highly branched three-dimensional macromolecules with unique 
molecular architectures that provide them with improved physical and chemical 
properties when compared to traditional linear polymers (Table 6). Dendrimers have 
received a great amount of attention in recent years as drug delivery systems due to the 
presence of cavities in their structure, which are used to improve the solubility and 
provide protection against degradation of therapeutic agents. Also, the external surface 
of the dendrimers can be functionalized with the therapeutic molecule of interest. For 
example, Lamanna et al.[125] reported the successful coupling of ibuprofen moieties at 
the periphery of the different generations of adamantane-based dendrons. A greater 
availability associated with the multivalent nature of ibuprofen-dendron conjugates may 
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be the underlying reason for the enhanced anti-inflammatory effect of this drug 
compared to the free formulation. Some reports have been focused on the use of 
dendrimers as solubilizing agents of NSAIDs in water in order to enhance the drug 
bioavailability. For example, several reports showed a significant enhancement of the 
solubility of different NSAIDs (ibuprofen, ketoprofen, indomethacin and diflunisal) 
when they were associated with different types of dendrimers such as polyamidoamine 
dendrimers[126–128], triazine based dendrimers[129], ethylenediamine or 
polypropyleneoxide cored polyamidoamine (PAMAM)[130] and cationic carbosilane 
dendrimers[131]. Several types of drug-dendrimer interactions involved in both the 
entrapment of the active pharmaceutical ingredient inside the dendritic structure and the 
interaction of the drug with the periphery of the dendrimer seem to be implicated in the 
dendrimer-mediated solubility enhancement[132]. 
MICELLES 
Micelles are formed by amphiphilic molecules, which self-assemble into nanosized 
core–shell structures at a level above that of the critical micellar concentration. During 
the past few decades, micelles have received growing scientific attention as drug 
delivery formulations due to their ability for solubilizing and stabilizing hydrophobic 
drugs in their inner core. In addition, their small size reduces the typically fast 
recognition by the mononuclear phagocytic system (Table 7). Scherlund et al.[133] 
demonstrated that a eutectic mixture of lidocaine and prilocaine loaded within mixed 
micelles possessed the required characteristics (proper gelation temperature, an 
adequate release profile and excellent long-term stability) for acting as a potential drug 
delivery formulation of anesthetics in the field of dentistry. A thermoresponsive mixed 
micellar nanogel system composed of lidocaine and prilocaine was also developed for 
topical delivery, attempting to improve pain relief therapy through localized delivery to 
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the site of action[134]. In this same manner, poloxamer (PL)-based binary hydrogels 
containing ropivacaine were prepared and characterized in order to prolong the duration 
of action of the local anesthetic ropivacaine and ameliorate the outcome during post-
operative pain relief application, obtaining regular release profiles and lower drug 
release percentages in comparison with free drug used for the same amount of 
time[135]. The synthesis of novel mPEG-PLA/Solutol® HS15 mixed micelles were 
optimized to achieve the efficient solubilization of anesthetic agent propofol and, 
thereby, solve some the drawbacks of other developed propofol formulations[136]. 
Aforementioned, the poor solubility and the relatively short plasma half-life of NSAIDs 
as well as the side effects associated with their use make these kinds of drugs ideal 
candidates to be encapsulated within micelles. For example, Bhat et al.[137] studied the 
solubilization of naproxen in micellar solutions composed of single, binary, and ternary 
surfactant combinations. In general, the solubilization capacity of mixed surfactant 
systems was better than those of single-surfactant. Kulthe et al.[138] encapsulated 
another NSAID, aceclofenac in Pluronic L81/P123 mixed micelles, obtaining high drug 
entrapment efficiency and a sustained release profile. Also, several strategies were used 
to load indomethacin in poly(ethylene oxide)-poly(β-benzyl L-aspartate) block 
copolymer micelles as an alternative approach to reduce the side effects of this NSAID. 
The finding of this study showed that the indomethacin release pattern from the 
synthetized micelles was pH-dependent, controlled probably by the partition coefficient 
of the drug and the interaction between indomethacin and the hydrophobic portion of 
the carrier system[139]. Wu et al.[140] reported the synthesis of ibuprofen loaded 
complex micelles made of a biodegradable PLA-based core and a mixed PEG/PNIPAM 
shell. At temperatures above the lower critical solution temperature of PNIPAM, the 
chains of this thermoresponsive polymer collapsed onto the PLA core, acting as barriers 
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for the diffusion of the drugs into and out of the micelle. Simultaneously, the PEG 
chains stretched through the collapsed PNIPAM shell, leading to the creation of 
hydrophilic conduits around them, which act as a passageway for drug release. 
Therefore, the ibuprofen diffused in a slow manner through the channels and its release 
rate could be controlled by modifying the size and permeability of the channels by 
varying the PEG/ PNIPAM chains ratio in the corona. 
SURFACTANT BASED SYSTEMS: NIOSOMES 
Niosomes are biodegradable, biocompatible, and non-immunogenic closed bilayer 
structures created by self-association of non-ionic surfactants and cholesterol in an 
aqueous phase (Table 8). Their special structure makes it possible for them to entrap 
both hydrophilic and lipophilic drugs into the aqueous core and the membrane bilayer of 
the niosome, respectively. Thanks to this and other outstanding characteristics such as 
biodegradability, biocompatibility, non-toxicity and non-immunogenicity, enhanced 
drug penetration and sustained drug release profile, niosomes are broadly used in topical 
drug delivery. 
Carafa et al.[141] studied the influence of different parameters such as vesicle 
composition and environmental pH condition in the encapsulation efficiency of 
lidocaine (free base form or hydrochloride) in different Tween20/Cholesterol vesicles. 
In addition, to analyze the influence of vesicle charge on therapeutic agent loading, 
dicetylphosphate and N-cetylpyridinium chloride were utilized to fabricate vesicles with 
negative and positive charge, respectively. Fluorescence quenching analyses showed 
that at pH similar to that of the skin (pH 5.5) the entrapment efficiency of lidocaine in 
positive and negative charged vesicles was negligible in compared to neutral vesicles. 
The obtained findings in diffusion experiments of drug loaded niosomal or liposomal 
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formulations through mouse abdominal skin exhibited the importance of non-ionic 
surfactant vesicles in dermal delivery of charged therapeutic agents[141].  
Polysorbate-20 derivatized by glycine was used to prepare pH-sensitive niosomes for 
delivering ibuprofen or lidocaine. A remarkable reduction in vesicle dimensions was 
observed after drug encapsulation without modification of the corresponding ζ-potential 
values when compared to empty ones. Loaded vesicles were stable for 1 month at 25ºC 
and their stability was not modified by the addition of serum at pH 7.4. Lidocaine 
interactions with the hydrophobic moiety of tween and the existence of electrostatic 
repulsive forces between the carboxyl group of ibuprofen and the polar niosome surface 
were noted as reasons to explain greater and reduced entrapment efficiency for lidocaine 
and ibuprofen, respectively[142]. Diclofenac sodium and aceclofenac have been also 
loaded in niosomes in an attempt to improve poor skin penetration as well as enhance 
skin drug retention, achieving high efficiency as topical anti-inflammatory 
formulations[143,144].  Moreover, aceclofenac, lornoxicam, meloxicam, nimesulide, 
rofecoxib and, diclofenac diethylammonium loaded niosomal dispersions were 
incorporated into gel matrixes to create topical formulations with increased skin 
permeation as a promising alternative to treat pain associated to various inflammatory 
conditions[145–151]. In general, anti-inflammatory activity of the cited niosomal gel 
formulation was significantly higher than that achieved with the free drug or other non-
niosomal gel formulation containing the free drugs. 
 
5.2.  INORGANIC NANOPARTICLE FORMULATIONS 
In spite of the non-biodegradability, inorganic materials have widely emerged as good 
candidates for the delivery of an extensive range of drugs, providing several advantages 
in drug delivery applications due to their unique physicochemical properties such as 
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facile preparation, versatility, good storage stability and biocompatibility. Among these, 
structured porous inorganic materials have been outlined in this field owing to their 
well-known intrinsic properties such as mechanical and chemical stability under 
physiological conditions, large inner surface areas and high surface to volume ratios, 
colloidal stability, tailorable pore sizes and possibility of specific functionalization of 
their pore walls. In the developing research field toward the use of these materials to 
adsorb or encapsulate a wide variety of drugs and modify their release kinetics, few 
research studies have addressed the development of silica-based nanocarriers as hosts 
for local anesthetics, nonsteroidal anti-inflammatory and opioid drugs for pain 
management (Table 9). In one study, Abd-Elrahman et al. [152] reported high 
ketoprofen loading on SBA-15 and a reduction of the loading time combining two 
commonly accepted for that purpose, which are immersion and rotavapor-based method. 
Although no significant differences in the anti-inflammatory response and central 
analgesic properties of the drug loaded SBA15 and the commercial product, Ketofan, 
were found after 120 minutes of administration, their onset of action was very different, 
obtaining therapeutic benefit more rapidly in the case of the encapsulated ketofan. Also, 
several studies reported the inclusion of NSAIDs such as piroxicam, ibuprofen and 
indomethacin in MCM-41 and SBA-15 mesoporous silicas with the objective of  
enhancing the bioavailability and pharmacokinetic profile of these poorly water-soluble 
drugs[153–156]. Overall, these in vitro studies demonstrated the ability of mesoporous 
silicas to improve the dissolution rate of the drug loaded, most likely overcoming the 
low oral availability problem of these poorly water-soluble drugs. However, little is 
known about the potential in vivo absorption improvement of these new formulations. 
A multifunctional drug delivery system using MCM-41 mesoporous silica nanoparticles 
loaded with a cannabinoid (Δ9- tetrahydrocannabinol) and an erythropoietin-derived 
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polypeptide with tissue-protective actions (ARA29) was designed as a therapeutic 
strategy for suppressing chronic neuropathic pain. The findings showed that those 
nanoparticles significantly attenuated the inflammatory response at in vitro and in vivo 
levels. Additionally, the authors described a more potent effect in cells treated with 
nanocomplexes in comparison with the corresponding single drug controls, suggesting 
the existence of an additive or synergistic pharmacological effect of both drugs[157]. 
Other nanoparticle drug-delivery vehicles that have been widely explored for their 
application in the biomedical field include metal nanoparticles such as gold, silver, 
platinum, palladium, and hybrid organic/inorganic NPs. Despite their important role in 
the biomedical field, to our knowledge there are no reports in the literature about the 
utilization of metal nanoparticles for pain relief, suggesting that this topic remains 
largely unexplored. 
Magnetic nanoparticles exhibit a wide variety of attributes, such as the intrinsic 
properties of their magnetic cores and their drug loading capability, which make them 
attractive platforms for targeted drug delivery. In particular, in the field of pain relief, 
magnetic nanocarriers functionalized with oleic acid and chitosan and diclofenac 
sodium-loaded Fe/ethylcellulose (core/shell) nanoparticles were developed as controlled 
diclofenac delivery systems for the treatment of inflammatory diseases[158,159]. Also, 
as drug carriers, they provide significant opportunities in locally targeted therapy (Table 
9). Magnetic carriers associated with drugs can be directed or guided by means of an 
external magnet towards certain organs or tissues. This approach was used as a proof of 
concept by Mantha et al.[160] to produce anesthetic ankle block in rats using magnetic 
nanoparticles and ropivacaine complexes driven by a magnet. Thirty minutes after the 
magnet application at the ankle of the animals intravenously injected with the optimized 
complexed, an increased thermal antinociceptive response was observed. Also, it is 
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important to mention that an enhancement of the safe dose of ropivacaine was achieved 
after its combination with magnetic nanoparticles. This same strategy was used by 
Nadri et al.[161] to design bupivacaine- loaded magnetic hydrogel-based 
nanocomposites in order to induce rat ankle block. Neither of the studies previously 
cited completed formal toxicity studies, indicating the necessity of carrying out further 
research to address questions indispensable for its translation to clinical practice.  
In the only previous study concerning the use of inorganic NPs without drugs as 
payload for pain relief, there was clear evidence that ultrasmall Fe3O4 NPs produce anti-
allodynia and anti-hyperthermia effects in a dose dependent manner in a chronic 
inflammatory pain model in mice. This analgesic response probably happens via 
attenuation of inflammatory cell infiltration and reduction of ROS production[162]. 
6. CLINICAL STUDIES 
Although nanoparticles present an exciting opportunity to obtain medical breakthroughs 
in the management of painful conditions, few clinical trials have been carried out and 
their current clinical use is limited.  
To date, the majority of cited clinical trials have been carried out to evaluate the 
efficacy of liposomal formulations loaded with local anesthetics in the dentistry field. A 
systematic meta-analysis of the literature including clinical trials using liposomal 
formulations loaded with local anesthetic reported varied results. For instance, 
infiltration of mepivacaine liposomal (3%) at maxillary level resulted in more prolonged 
pulpal and soft-tissue anesthesia than the unloaded mepivacaine at the same 
concentration[34]. However, a randomized, double-blind, crossover design clinical 
study involving 40 healthy volunteers carried out to analize the efficiency of 
ropivacaine liposomal (0.5%) in dental anesthesia compared to three other local 
anesthetic combinations showed liposome encapsulation did not improve the anesthetic 
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effectiveness of ropivacaine for this anesthetic technique in humans[163]. Another 
comparative clinical trial was conducted in 40 volunteers to analyze the influence of 
liposome-encapsulated 2% ropivacaine on pulpal response in comparison with those 
observed with other topical formulations.  The study concluded that although the dose 
of liposomal ropivacaine was effective to promote soft tissue anesthesia and to reduce 
pain during needle insertion, it was insufficient in inducing pulpal anesthesia[164]. A 
similar study carried out previously by the same authors showed equivalent results in 
relation to inducing pulpal anesthesia after topical application of liposome-encapsulated 
ropivacaine (1%)[165]. However, it is worth indicating that none of the studied topical 
formulations in both studies were able to induce pulpal anesthesia either. No significant 
differences were observed either between prilocaine loaded liposomes (3%) and free 
prilocaine or free prilocaine plus a vasoconstrictor[166]. The comparison of results 
obtained from different formulations in clinical trials remains difficult due to wide range 
of tested local anesthetics and selected doses in human trials. 
Among the various routes of administration used, topical anesthesia plays a pivotal role 
in the control of pain and, therefore, in the comfort and safety of patients during clinical 
and diagnostic procedures. Several studies have also demonstrated that the 
encapsulation of local anesthetics in liposomes provides significant benefits for 
prevention of procedural pain. For example, the efficacy of liposomal lidocaine was 
evaluated during the dermal procedure of intravenous cannulation in children showing 
successful clinical benefits such as higher intravenous cannulation rate, less pain, 
shorter total procedure time and minor dermal changes[167]. Also, Franz-Montan et 
al.[168] showed in healthy volunteers that a topical gel composed of liposome-
encapsulated (5%) lidocaine effectively increased the duration of tissue anesthesia and 
reduced pain during needle insertion with the same efficacy than commercially 
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available formulation EMLA®, making is a good candidate for efficient and effective 
topical anesthetic in dentistry.  
The efficacy of NSAID skin-delivery systems based on liposomal based formulations 
was also demonstrated on healthy volunteers with UVB-induced erythema [169]. For 
example, the cutaneous application of indomethacin- loaded liposomes incorporated into 
hydrogels provided a more extended anti-inflammatory response compared to system 
composed of gel and the free drug, probably associated to a controlled release rate of the 
active ingredient to deeper skin layers in consequence of the interaction of loaded 
liposomes with the stratum corneum. 
Similar results were observed in two independent studies after the indirect evaluation of 
ketopren or naproxen and indomethacin percutaneous absorption from NLC by 
monitoring the effect on on healthy human volunteers with UVB-induced erythema. In 
both cases, an extended and targeted anti-inflammatory response was observed, 
reflecting the grand potential of NLC as vehicles for dermal delivery[87,88]. 
Finally, it is noteworthy to mention that two drug delivery nanocarriers are already on 
the market. Diprivan®, an injectable emulsion formulation of propofol, was approved by 
FDA in 1989 for its utilization in the induction and maintenance of anesthesia or 
sedation in adults. Also, DepoDur®, an extended-release injectable formulation of 
morphine, was approved by the FDA in 2004 for the treatment of pain following major 
surgery. The efficacy of DepoDur® was demonstrated in different clinical trials 
performed in 876 patients undergoing surgical procedures such as hip arthroplasty, 
prostatectomy, colon resection and cesarean section. NKTR-119 is an investigational 
drug candidate based on the combination of Movantik® (naloxegol) and an opioid 
analgesic for pain relief without the gastrointestinal side effects associated with habitual 
opioid treatments.  
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Over the past few decades, the research on drug formulations has been aimed primarily 
at the design of drug delivery systems, which are capable of delaying and sustaining 
drug release and achieving selective delivery to specific physiological sites. Particulate 
drug-delivery formulations based on micro- and nanoparticles have become prominent 
in research as an alternative to overcome most of the shortcomings associated with 
traditional pharmaceuticals (instability, unfavorable pharmacokinetics, high toxicity, 
poor solubility and low cellular uptake). Particulate drug-delivery systems offer many 
advantages, including high drug stability, feasibility of incorporating hydrophilic and 
hydrophobic active principles, drug protection from degradation, modification of 
pharmacokinetics and drug tissue distribution profiles, improved efficacy, reduced 
toxicity, increase of drug circulation time (when intravenously administered), and a 
decrease of nonspecific uptake. Also, nanostructured materials show exceptional 
physicochemical properties such as small and controllable size, large surface area to 
volume ratio, high reactivity, and functionalizable structure. A number of micro- and 
nanoparticle-based therapies have been approved by the FDA for clinical use, 
highlighting the benefit of these drug formulations in the development of health care 
products for the area of pharmacology [170,171]. Specifically, in 2011, a bupivacaine 
liposomal injectable suspension, commercially named Exparel™, was approved by the 
FDA for single-dose administration into the surgical site to produce postsurgical 
analgesia in adults. The FDA approval of Exparel™ was based on two multicenter, 
randomized, double-blind clinical trials that evaluated their efficacy versus placebo in 
the treatment of patients undergoing two different surgeries, hemorrhoidectomy and 
bunionectomy. The use of  bupivacaine loaded liposomes has proved to be a highly 
effective and safe treatment with adequate pharmacokinetics and pharmacodynamics 
reducing the risk of systemic toxicity[172,173]. Although Exparel™ was approved by 
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FDA exclusively for postsurgical analgesia in adults, several studies about their use in 
peripheral nerve blockade have been carried out in recent years. In the absence of 
published animal data about Exparel™’s biocompatibility in proximity to major nerves 
and muscles, McAlvin et al.[174] decided to determine the efficacy of this new 
bupivacaine liposomal formulation in sciatic nerve in rat models and evaluate their 
biocompatibility in near nerve tissues, comparing its effects with those of two different 
concentrations of bupivacaine HCl in its free form (0.5 and 1.3 % (w/v), a concentration 
of bupivacaine used in clinical practice and a concentration of bupivacaine equal to that 
in Exparel™, respectively). Histological evaluation at four days post-injection reported 
that both Exparel™ and bupivacaine hydrochloride 0.5% (w/v) produced a similar 
degree of myotoxicity and local tissue inflammation, consisting of a mixed 
inflammatory infiltrate in the soft tissues surrounding the muscle. However, in the case 
of Exparel™, the macrophages had a foamy cytoplasm; likely reflecting uptake of the 
lipid-rich particles and, in addition, inflammation lasted much longer. The histological 
findings also showed that inflammation and myotoxicity degrees were more severe in 
the case of bupivacaine HCl compared to that of encapsulated in Exparel™ when using 
equal concentrations. No neurotoxicity was observed in any of the treatment groups. In 
another preclinical study, conducted in rabbits and dogs to evaluate the potential safety 
of Exparel™, no local signs of toxicity were observed. The minimal to mild 
granulomatous inflammation of adipose tissue seen around nerve roots was associated 
with a nonspecific foreign-body type reaction[175]. In spite of the successful results 
obtained in preclinical studies, the data collected from 6 prospective and controlled 
clinical studies for the use liposomal bupivacaine in peripheral nerve blockade did not 
render sufficient data to obtain a final conclusion about their safety profile when utilized 
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in distinct classes of nerves in heterogeneous patient populations[176] and, thus, a more 
exhaustive evaluation has to be conducted. 
More recently, the Company Heron Therapeutics, Inc. has developed an extended 
release biochronomer-based delivery system (HTX-011) that contains bupivacaine and 
meloxicam, as a preventative treatment for post-operative pain. BiochronomerTM 
technology consists of bioerodible polymers designed to release drug over long periods 
of time. Data from four phase II clinical trials evaluating HTX-011 as a preventative 
treatment for post-operative pain in several types of surgeries, including bunionectomy, 
hernia repair, and abdominoplasty, showed significant improvements in pain and 
reductions in opioid use. HTX-011 can be administrated by both injection and 
instillation. The evaluation of its efficacy and safety in an ongoing phase 2 randomized, 
controlled, multicenter study shows that the treatment with HTX-011 by injection or 
instillation is tolerated similarly well by patients undergoing elective open inguinal 
hernia repair [177]. In light of the obtained positive outcomes, a phase III clinical trial 
has been recently initiated by Heron Therapeutics, Inc. Company. 
 
7. CONCLUSIONS 
Over the last few decades, nanomedicine is enabling the development of numerous 
biocompatible nanoparticule drug carriers for their use in therapeutic applications, 
contributing significantly to the progress of medical science. Scientific evidence 
demonstrates that the nanoencapsulation of different painkillers in nanostructured 
carriers shows clear advantages compared to the administration of the drugs in their free 
form including the improvement of the drugs bioavailability and pharmacokinetic 
profiles and minimized side-effects. To translate these advances into clinical practice, it 
is necessary to perform an initial evaluation of novel nanotechnology-derived 
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pharmaceutical platforms in extensive in vivo clinical studies to achieve detailed 
information about the pharmacologic effects of administered materials in terms of 
efficacy and to determinedosing and toxicity levels with the objective of predicting 
possible adverse effects. Some of those nanostructured formulations have already 
reached the market highlighting the potential of the field to fulfill the unmet needs and 
to overcome the existing limitations in pain management.  
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Table 1. Liposomal formulations for pain management described in the literature. 
Nanoparticle 
Type 
Drug 
In vitro 
evaluati
on 
 
In vivo 
evaluation 
 
Administra
tion Route 
Outcomes 
Refere
nce 
Liposomes       
 
Local 
anesthetic 
     
Liposomes 
Prilocaine, 
lidocaine or 
mepivacaine 
-  
Infraorbital 
nerve 
blockade test 
in rats 
- 
Increased 
analgesic 
duration 
and 
intensity 
for the 
three local 
anesthetics 
after their 
encapsulati
on 
[30] 
Liposomes Prilocaine - 
Infraorbital 
nerve 
blockade test 
in rats 
- 
Prolonged 
anesthesia 
duration 
[31] 
Liposomes Prilocaine - 
Local Toxicity 
Evaluation 
(paw edema 
test) 
Histological 
Analysis after 
administratio
n in the oral 
mucosa of 
the right-
upper first 
molar 
Intraplanta
r  
No 
inflammato
ry effects  
 Less 
inflammato
ry reaction 
in the rat 
oral 
mucosa 
than that 
achieved by 
a 
commercial 
vasoconstri
ctor-
containing 
[32] 
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formulation 
Liposomes Ropivacaine 
Cytotoxi
city 
assay in 
sciatic 
nerve  
Schwan
n cells 
Infraorbital 
nerve 
blockade test 
in rats  
Sciatic nerve 
blockade test 
in mice 
Injection 
into the 
mouse 
sciatic 
nerve 
Improved 
analgesic 
effect  
Decreased 
cytotoxicity 
of drug in 
comparison 
with the 
free drug  
[33] 
Liposomes Mepivacaine - 
Local toxicity 
study in rats 
Intra-oral  
Liposomal 
drug might 
protect the 
tissue 
against 
local 
inflammati
on 
[34] 
Liposomal gel Lidocaine - 
Ex vivo 
permeation 
study across 
pig palatal 
mucosa 
- 
The highest 
permeation 
compared 
to other 
formulation
s 
[167] 
 NSAIDs      
Liposomes Diclofenac  
Mechanical 
and thermal 
hyperalgesia 
evaluation in 
rats 
Oral  
Enhanced 
antinocicep
tive effects 
[36] 
Liposomes 
carrying 
hyaluronan 
or collagen 
on their 
surface 
Diclofenac 
Liposom
e-cell 
binding 
study in 
differen
t cell 
lines 
- - 
Increased 
retention 
of the 
liposomes 
in the 
targeted 
area  
[37] 
Liposomes 
carrying 
Diclofenac 
and/or 
- 
Evaluation of 
anti- Intra-
 Reduced 
inflammati
[38] 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
hyaluronan 
or collagen 
on their 
surface 
dexametason
e 
inflammatory 
activity  in 
osteoarthritis 
model rat 
articular  
 
on volume 
compared 
to the 
untreated 
animals 
Liposomal gel Ibuprofen - 
Ex vivo 
permeation 
accross pig 
dural 
membrane 
- 
Increased 
dural 
permeation 
of 
ibuprofen 
compared 
with the gel 
control 
[39] 
Ultradeforma
ble, 
deformable 
and 
conventional 
liposomes 
Meloxicam 
Skin 
Permeat
ion 
Study 
across 
excised 
skin of 
hairless 
mice 
- - 
An efficient 
carrier for 
transderma
l drug 
delivery  
[41] 
 Opioids      
Multilamellar 
liposomes 
Morphine, 
fentanyl, 
alfentanil  
and 
sufentanil 
- 
Microdialysis 
experiments 
 
Different 
parameters 
such as 
drug 
hydrophobi
city and 
lipid 
content of 
the 
liposomes 
modulate 
drug 
distribution 
in vivo 
[42] 
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Liposomes 
Oxymorphon
e 
 
In vivo 
pharmacokin
etic assays. 
Thermal 
hyperalgesia 
analysis in 
neuropathic 
pain rat 
model 
Subcutane
ous  
Long-term 
analgesia 
[43] 
Liposomes 
Hydromorph
one 
- 
Thermal 
hyperalgesia 
analysis in 
neuropathic 
pain rat 
model 
Subcutane
ous  
Prolonged 
relief  
[44] 
Immunolipos
omes 
Loperamide 
Cellular 
Uptake 
of 
Liposom
es in 
primary 
high 
endothe
lial 
venule 
cells 
Antinocicepti
ve and 
inflammatory 
testing in 
acute 
inflammatory 
pain rat 
model 
Intravenou
s 
 
Analgesic 
and anti-
inflammato
ry effects 
exclusively 
in 
peripheral 
painful 
inflamed 
tissue 
[45] 
RGD peptide 
anchored  
liposomes 
Fentanyl - 
Pharmacokin
etic study 
and analgesic 
pharmacody
namic effect 
analysis in 
rats 
Intranasal 
(POD 
device) 
More 
gradual, 
long-lasting 
analgesic 
effect in 
comparison 
with the 
free drug  
[46] 
Phototrigger
able 
liposomal 
device 
Tetrodotoxin 
Cytotoxi
city 
studies 
C2C12 
and 
PC12 
Neurobehavi
oral testing 
and 
histological 
studies in 
rats 
Intramuscu
lar  
Not 
cytotoxic 
formulation
s in vitro 
and in vivo 
Light-
sensitive 
[47] 
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cells  
 
liposomes 
induced 
sensory 
and motor 
nerve block 
Gold 
nanorods 
attached to 
low 
temperature 
sensitive 
liposomes 
Tetrodotoxin 
and 
dexmedetom
idine 
Cytotoxi
city 
studies 
C2C12 
and 
PC12 
cells 
Nociceptive 
behavioral 
testing in rats 
Intraplanta
r  
On-demand 
infiltration 
anesthesia 
or sciatic 
nerve 
blockade 
with 
minimal 
toxicity 
[48] 
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Table 2. Ethosomal formulations for pain management described in the literature. 
Nanoparti
cle Type 
Drug 
In vitro 
evaluation 
 
In vivo 
evaluation 
 
Administrat
ion Route 
Outcomes 
Referen
ce 
Ethosome
s 
      
 
Local 
anesthetic 
     
Ethosome
s 
Ropivacain
e 
-  
Ex vivo 
permeation 
study in 
dorsal skin 
mice 
Vesicle-skin 
interaction 
histopatholog
ical study 
- 
Increased 
transdermal 
drug flux  
Modified the 
stratum 
corneum 
structure by 
the 
interaction 
ethosomes-
skin 
[49] 
Ethosome
s 
Lidocaine 
In vitro rat 
skin 
permeatio
n and drug 
deposition 
studies 
- - 
Skin 
penetration 
of drug and 
deposition 
of 
nanoethoso
mes in deep 
skin layers 
[50] 
Ethosome
s 
Lidocaine 
In vitro 
Percutane
ous 
Penetratio
n across 
rat 
abdominal 
skin 
In vivo 
Cutaneous 
Irritancy 
study 
Topical  
Excellent 
percutaneou
s drug 
penetration 
from 
ethosomes 
 No evidence 
of skin 
erythema or 
swelling 
[51] 
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Ethosomal 
gel 
Benzocain
e 
In vitro 
permeatio
n studies 
using 
artificial 
membrane
s 
simulating 
epidermal 
barrier  
Anesthetic 
activity study 
in rabbit 
Topical  
Increased 
intensity and 
duration of 
anesthetic 
effect 
[52] 
 NSAIDs      
Ethosome
s 
Ketopren 
In vitro 
permeatio
n studies 
through 
adult 
Chinese 
female 
skin 
- - 
Improved 
drug 
permeation 
and higher 
transdermal 
flux  
[53] 
Ethosomal 
gel 
Diclofenac 
sodium 
Skin 
permeatio
n and drug 
deposition 
studies in 
rat skin 
- - 
Ethosomal 
formulations 
can act as 
drug 
reservoir in 
skin and 
extend the 
pharmacolo
gic effects 
[54] 
Ethosome
s 
Aceclofena
c 
- 
Ex vivo 
permeation 
studies 
through mice 
abdominal 
skin 
Anti- 
inflammatory 
activity study 
in 
carrageenan-
induced rat 
paw edema 
Topical  
Superior 
drug 
permeation 
and 
retention in 
comparison 
with 
conventional 
drug-
containing 
products 
[55] 
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model 
 
Ethosome
s 
Diclofenac 
sodium 
In vitro 
skin 
permeatio
n study 
through 
rat 
abdominal 
skin 
Anti-
inflammatory 
activity study 
in 
carrageenan-
induced rat 
paw edema 
model  
Topical  
Increased  
permeation 
and anti-
inflammator
y activity 
compared to 
control 
formulations 
[56] 
Ethosomal 
gel  
Piroxicam 
In vitro 
permeatio
n study  
- - 
Significant 
amount of 
drug 
transported 
across the 
skin when 
entrapped in 
ethosomes 
[57] 
Ethosomal 
gel 
ibuprofen - 
Analgesic 
effect study 
in mice. Skin 
histological 
examination. 
Trandermal 
 
Drug 
ethosomal 
gel is safe  
Systemic 
antinocicepti
ve effect in 
rats 
[58] 
Ethosomal 
gel 
Aceclofena
c 
In vitro 
skin 
permeatio
n study 
through 
rat skin 
Anti-
inflammatory 
activity study 
in 
carrageenan 
induced rat 
paw edema 
model 
Topical  
Improved 
anti-
inflammator
y activity in 
comparison 
with other 
control 
formulations 
[59] 
Ethosomal 
gel 
Lornoxica
m 
In vitro 
diffusion 
study 
using 
cellophane 
Anti-
inflammatory 
activity study 
in 
carrageenan 
induced rat 
Topical  
Enhanced 
anti-
inflammator
y 
activity of 
[60] 
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membrane paw edema 
model 
ethosomal 
gel  
Ethosomal 
gel 
Indometha
cin 
- - - 
Higher 
entrapment 
efficiency 
for 
ethosomes 
than 
liposomes  
Increased 
viscosity and 
stability of 
the gel 
formulation 
[61] 
Ethosomal 
gel 
Meloxicam In vitro 
skin 
permeatio
n study 
Anti-
inflammatory 
activity study 
in 
carrageenan 
induced rat 
paw edema 
model  
Topical  Higher 
inhibition of 
swelling of 
rat paw 
edema by 
drug 
ethosomal  
gel 
compared 
with other 
formulations 
[62] 
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Table 3. Solid lipid nanoparticles (SLNs) for pain management described in the 
literature. 
Nanoparti
cle Type 
Drug In vitro 
evaluati
on 
 
In vivo 
evaluation 
 
Administra
tion Route 
Outcomes Refere
nce 
Solid Lipid 
Nanoparti
cles (SLNs) 
      
 Local 
anesthetic 
     
SLNs Lidocaine -  Neurobehavio
ral testing and 
histological 
studies in rats 
Epidural  Extended 
anesthetic 
effect with all 
tested 
formulations  
[63] 
SLNs  gel 
formulatio
n 
Benzocaine - Ex vivo 
permeation 
studies in rat 
skin 
Analgesic 
effect analysis 
in rats 
Topical  Higher drug 
permeation 
compared to 
free drug 
 Improved 
intensity and 
duration of 
anesthetic 
effect 
[64] 
SLNs gel 
formulatio
n 
Lidocaine Skin 
permeati
on 
studies 
using 
hairless 
abdomin
al 
guinea 
pig skin 
Efficacy 
evaluation of 
gel 
formulations 
on pigs 
Topical  Sustained 
release from 
SLNs and 
increased 
anesthesia 
duration 
[65] 
SLNs Indometha
cin 
In vitro 
corneal 
- - Improved 
corneal drug 
[66] 
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permeati
on 
studies 
and 
histologi
cal 
studies 
permeability 
after 
encapsulation 
No major 
structural 
damage to 
the 
corneal 
epithelium 
SLNs and 
Chitosan-
SLNs 
Indometha
cin 
In vitro 
corneal 
and 
sclera-
choroid-
RPE 
permeati
on 
studies  
In vivo 
bioavailability 
studies in 
rabbits 
Topical 
application 
Increased 
ocular drug 
penetration 
after surface 
modification 
with chitosan 
Superior 
transmembra
ne drug 
permeation 
compared to 
SLNs 
 
[67] 
 NSAIDs      
SLNs Naproxen In vitro 
skin 
permeati
on study 
in rat 
abdomin
al skin 
- - Increased 
drug 
concentratio
n at the top 
layers of the 
skin 
[68] 
SLNs and 
oleic acid-
SLNs 
Piroxicam In vitro 
transder
mal 
efficienc
y of the 
piroxica
m from 
SLNs 
Anti-
inflammatory 
effect study in 
a 
carrageenan-
induced rat 
paw edema 
model 
Topical 
administrat
ion 
Decreased 
inflammatory 
responses in 
the edema 
site and 
reduced 
secretion of 
inflammatory 
cytokines 
[69] 
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Oleic acid-
SLNs 
significantly 
promoted the 
skin drug 
penetration  
SLNs gel 
formulatio
ns 
Diflunisal -  Ex vivo 
permeation 
studies across 
mice skin. 
Pharmacodyn
amic 
evaluation in 
three 
different 
animal 
models  
Topical 
administrat
ion 
Better 
permeation 
as well as skin 
retention 
compared to 
conventional 
formulations 
High-efficacy 
therapeutic 
effects 
[70] 
SLNs Celecoxib -  Biodistributio
n, 
pharmacokine
tic and 
histological 
studies in 
Sprague 
Dawley rats 
Intra-
articular  
Enhanced 
retention in 
the joint and 
reduced 
uncontrolled 
distribution 
to other 
organs 
Reduced 
toxicity of the 
drug and 
prolongation 
of their 
effects  
Assured 
biocompatibil
ity 
[71] 
 Opioids      
SLNs Buprenorp
hine and its 
prodrugs 
- Evaluation of 
analgesic 
effect in 
Sprague-
Intravenou
s  
Moderate 
release, 
prolonged 
antinocicepti
on and low 
[72] 
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Dawley rats toxicity 
SLNs Morphine Evaluatio
n of 
effect in 
3D-
wound 
healing 
model 
- - Unloaded 
and drug-
loaded 
SLN 
promoted 
wound 
reepithelializ
ation 
[73] 
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Table 4. Nanostructured lipid carriers (NCLs) for pain management described in the 
literature. 
Nanopartic
le Type 
Drug 
In vitro 
evaluation 
 
In vivo 
evaluation 
 
Administra
tion Route 
Outcomes 
Refere
nce 
Nanostruct
ured lipid 
carriers 
(NLCs) 
      
 
Local 
anesthetic 
     
NLC 
Benzocain
e or 
Lidocaine 
In vitro Skin 
Permeation 
Experiment
s 
Antinocicepti
on test in 
mice 
Topical  
Decreased 
drug 
permeation 
through the 
skin and 
prolonged 
antinocicepti
ve effect  
[75] 
Folate 
functionaliz
ed NLC 
Lidocaine 
and 
Prilocaine 
- - - - 
[77] 
 NSAIDs      
NLC Oxaprozin 
Cell 
viability 
assay and 
cell uptake 
in 
RAW264.7 
cells and 
cell 
permeabilit
y studies in 
Caco2 cells  
- - 
NLC are not 
toxic  
Enhanced 
cell uptake 
over time  
Encapsulatio
n did not 
interfer with 
oxaprozin 
permeability 
[78] 
NLC 
Flurbiprofe
n 
- 
In vivo Draize 
test 
(irritation 
Topical  
Minimal 
irritation 
[79] 
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test) in 
rabbits 
NLC 
Indometha
cin 
In vitro 
corneal and 
sclera-
choroid-
RPE 
permeation 
studies 
In vivo 
bioavailabilit
y studies in 
rabbits 
Topical  
Higher drug 
concentratio
ns in all 
ocular 
tissues 
tested 
[67] 
NLC 
Flurbiprofe
n 
In vitro 
permeation 
studies 
through rat 
abdominal 
skin  
 - - 
Improved 
permeated 
drug amount 
[80] 
NLC  
Flurbiprofe
n 
In vitro rat 
skin 
permeation 
studies 
Anti-
inflammatory 
activity 
evaluation in 
rats and 
pharmacokin
etic studies 
Topical  
Increased 
drug 
bioavailabilit
y, sustained 
drug release 
and 
better 
therapeutic 
effect up to 
24 h 
compared 
with the 
commercial 
gel 
[81] 
NLC 
Lornoxica
m 
Drug 
penetration 
through rat 
skin 
- - 
Increased 
skin 
penetration 
rate of the 
drug 
compared to 
a traditional 
gel 
formulation 
[82] 
NLC Ibuprofen Biocompati
bility 
- - The 
formulations 
[83] 
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studies in 
Y-79 cells 
were safe at 
the 
concentratio
ns tested 
NLC based 
gel 
formulatio
n 
Celecoxib 
In vitro rat 
abdominal 
skin 
permeation 
studies 
Pharmacody
namic 
efficacy 
Topical  
Rapid onset 
of action of 
the NLC gel 
[84] 
NLC based 
gel 
formulatio
n 
Meloxicam 
Toxicity 
screening 
Ex vivo rat 
abdominal 
skin 
permeation 
and skin 
deposition. 
Pharmacody
namic 
activity study 
in a 
carrageenan 
induced rat 
paw edema 
volume 
model 
Topical  
Hemocompa
tible, non-
irritant and 
nontoxic gel 
formulation 
Improved 
skin 
permeation 
and 
deposition 
 NLC based 
gel showed 
higher anti-
inflammator
y effect than 
the drug gel 
[85] 
NLC based 
gel 
formulatio
n 
Meloxicam - 
In vivo 
visualization 
of skin 
penetration 
Pharmacokin
etic study in 
rat 
 Toxicity 
study in mice 
and skin 
irritation 
study in 
rabbit 
 
Topical  
Good skin 
tolerability 
and 
biosafety 
Improved 
skin drug 
penetration 
Pronounced 
analgesic 
effect of the 
NCL-based 
gel 
[86] 
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NLC 
Indometha
cin 
Human skin 
membrane 
permeation 
study 
Anti-
Inflammatory 
activity in 
humans 
Topical  
Delayed and 
sustained 
activity of 
drug loaded 
NLC 
formulation 
[87] 
NLC 
Ketoproph
en and 
naproxen 
In vitro skin 
permeation 
experiment 
Anti-
Inflammatory 
activity in 
humans 
Topical  
Extended 
anti-
inflammator
y effect of 
loaded 
active 
molecules, 
providing 
prolonged 
release in 
the 
epidermis 
[88] 
NLC based 
gel 
formulatio
n 
Valdecoxib - 
Skin irritation 
studies. 
Pharmacody
namic 
efficacy in 
aerosil-
induced rat 
paw edema 
method 
 
No signs of 
skin 
irritation  
Faster onset 
and 
prolonged 
anti-
inflammator
y activity 
with NLC 
formulations 
[89] 
 Opioids      
SLNs 
Buprenorp
hine and 
its 
prodrugs 
- 
Analgesic 
effect 
evaluation in 
Sprague–
Dawley rats 
Intravenou
s  
Moderate 
release, 
prolonged 
antinocicepti
on and low 
toxicity 
[72] 
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Table 5. Polymeric nanocarriers for pain management described in the literature. 
Nanoparticle 
Type 
Drug 
In vitro 
evaluation 
 
In vivo 
evaluation 
 
Administ
ration 
Route 
Outcomes 
Refer
ence 
Polymer NPs       
 
Local 
anestheti
c 
     
PLGA 
nanospheres 
(NS) 
Ropivacai
ne 
Cytotoxic 
Assays in 
Balb/c 
mouse 
fibroblasts 
- - 
PLGA-NS had 
no effect on 
cell viability. 
 
[90] 
PLGA 
nanocapsules  
Benzocai
ne 
Cytotoxic 
Assays in  
Balb/c 
mouse 
fibroblasts  
- - 
No cytotoxic 
effect at 
tested 
concentration
s 
[91] 
PLGA 
nanocapsules 
Bupivacai
ne 
- - - 
Good 
physicochemi
cal stability 
[92] 
PLGA NPs 
Bupivacai
ne 
- 
Analgesic 
effect 
analysis in 
rats and 
and anti-
allodynic 
effect 
analysis 
chronic 
constrictio
n injury rat 
model 
Subplant
ar region  
Longer and 
higher 
analgesic 
and anti-
allodynic 
activity in 
comparison 
to non-
encapsulated 
drug 
 
[93] 
PLGA 
nanocapsules 
Benzocai
ne 
- 
Sciatic 
nerve 
blockade 
evaluation 
Intramus
cular  
Increased 
duration of 
motor 
blockade  
[94] 
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in mice Increased 
duration and 
intensity of 
the 
antinociceptiv
e effect in 
comparison 
to the free 
drug 
PCL 
nanospheres 
Lidocaine 
Cell viability 
assay in 
Balb-c 
mouse 3T3 
fibroblasts 
Sciatic 
nerve 
blockade 
evaluation 
in mice 
 
Reduced 
toxicity  
Motor 
blockade 
were not 
affected 
Intense and 
prolonged 
analgesic 
effect of the 
optimized 
nanoformulat
ion 
[95] 
PLA or PCL 
nanocapsules 
Benzocai
ne 
- 
Sciatic 
nerve 
blockade 
evaluation 
in mice 
Intramus
cular  
Enhanced 
anesthetic 
effect of 
benzocaine 
after its 
encapsulation 
[96] 
Alginate/chitos
an NPs and 
alginate/bis(2-
ethylhexyl) 
sulfosuccinate 
NPs 
Benzocai
ne 
Cytotoxicity 
assays in 
Balb-c 
mouse 3T3 
fibroblasts 
Sciatic 
nerve 
blockade 
evaluation 
in mice 
Intramus
cular  
Increased 
duration and 
intensity of 
the anti-
nociceptive 
effect in 
comparison 
to the non-
encapsulated 
drug 
[97] 
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Alginate/chitos
an 
nanospheres 
and PEG-PCL 
nanocapsules 
Articaine 
Cytotoxicity 
assays in 
Balb-c 
mouse 3T3 
fibroblasts 
- - 
Drug 
encapsulation 
reduced its 
cytotoxicity 
[98] 
 NSAIDs      
Eudragit® RL 
and PLGA NPs 
Piroxicam  Rats 
Intra-
articular  
Prolonged 
drug 
retention in 
the joint 
[99] 
Eudragit-S100 
NPs 
Ibuprofen - - - 
Good 
stability, 
maximum 
entrapment 
efficiency and 
sustained 
drug release  
[100] 
Eudragit® L100 
and Eudragit® 
L100/PLGA NPs 
Diclofena
c Sodium 
- - - 
The amount 
of Eudragit in 
the blend 
influenced in 
the 
encapsulation 
efficiency and 
the drug 
release 
profile 
[101] 
PCL-, PLA-, or 
PLGA-NPs 
Celecoxib 
Cytotoxicity 
assay in 
HEK293 
cells 
- - 
Excellent 
biocompatibil
ity 
[102] 
N-
Trimethyl/Chit
osan NPs 
Diclofena
c Sodium 
Eye 
Irritation 
test in 
rabbit 
corneal cell 
line cells 
Eye 
irritation 
test and 
drug 
absorption 
study in 
albino 
rabbits 
Ophthal
mic  
Drug -loaded 
nanoparticles 
were safe for 
ophthalmic 
use. 
Improved 
ophthalmic 
drug 
[103] 
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bioavailability 
PCL NPs 
Meloxica
m 
- 
Anti-
inflammato
ry activity 
evaluation  
in 
carrageena
n-induced 
paw edema 
model 
(Sprague-
Dawley 
rats) 
Ulcerogeni
c study in 
the ulcer 
model 
Oral  
Higher 
activity anti-
inflammatory 
effect for a 
longer 
duration 
Lower 
ulceration 
index than 
a free drug 
suspension 
[104] 
PEGylated 
gelatin 
nanoparticles 
Ibuprofen 
Sodium 
Hemocomp
atibility, 
plasma 
coagulation, 
platelet 
activation 
and 
aggregation
, 
inflammator
y response 
and 
cytokine 
induction 
lymphocyte 
proliferatio
n, 
suppression 
and toxicity 
studies 
Cytokine 
induction 
studies, 
pharmacok
inetic 
analysis 
and 
histological 
analysis in 
Sprague 
Dawley rats 
Intraveno
us  
Non-toxic, 
hemocompati
ble and 
nonimmunog
enic NPs 
Sustained 
drug release 
for 4 days 
with 
improved 
bioavailability 
and 
pharmacokin
etics 
 
[105] 
Eudragit® L 100 
nanocapsules 
Indometh
acin 
Cytotoxicity 
study in 
HepG2 cells 
Genotoxicit
y study and 
- - 
Nanocapsules 
were not 
cytotoxic to 
lymphocytes 
and HepG2 
[106] 
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cytokinesis-
block 
micronucleu
s cytome 
assay in 
HepG2 cells 
and Human 
peripheral 
blood 
lymphocyte
s 
cells  
Only the 
highest 
concentration 
tested caused 
a small 
increase 
in 
micronucleat
ed cells, 
indicating a 
clastogenic/a
neugenic 
effect 
Ethyl cellulose-
based NPs 
Piroxicam - 
Drug 
profile in 
blood 
samples, 
pharmacok
inetic 
study, 
histological 
examinatio
n and 
gastric 
irritation 
test in 
Wistar rats 
Oral  
Time to reach 
maximum 
plasma 
concentration 
was 
significantly 
higher than 
that of 
commercial 
capsules  
Drug 
encapsulation 
into NPs 
suppressed 
significantly 
gastric 
ulceration 
potential in 
rats 
 
[107] 
PEGylated 
PLGA 
nanospheres 
Dexibupr
ofen 
Short-term 
stability 
Cytotoxicity 
assay 
human 
retinoblasto
Ex vivo 
corneal 
and scleral 
permeation 
experiment
s in rabbits 
Ophthal
mic  
Significantly 
reduced cell 
viability  
Increased 
tropism to 
the cornea 
[108] 
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ma cell line. 
Ocular 
tolerance 
assays: HET-
CAM 
Ocular 
tolerance 
assays: 
Draize 
irritation 
test 
Inflammato
ry activity 
assay 
Ocular drug 
bioavailabil
ity 
enhancing 
drug 
retention and 
permeation 
Good ocular 
tolerance 
Nanospheres 
were 
effective both 
preventing 
and treating 
inflammation 
Polypyrrole 
nanoparticles  
Piroxicam - - - 
Sustained 
drug release 
profile   
[110] 
Pullulan-g-
poly(N-
isopropylacryla
mide) NPs 
Indometh
acin 
- - - 
Drug loaded 
polymeric 
particles  
prepared by 
different 
methods  
High drug 
entrapment 
efficiency  
In vitro drug 
release 
depended on 
different 
parameters 
[111] 
 Opioids      
Lactoferrin or 
transferrin 
anchored PLGA 
nanoparticles 
Tramadol 
hydrochlo
ride 
- 
Antinocice
ptive test 
in mice 
Intraveno
us  
Extended 
antinociceptiv
e effect 
[112] 
8D3-PLGA 
nanoparticles 
Loperami
de 
Cell viability 
assay in 
HeLa and 
MDR-MDCK 
Antinocice
ptive test 
in mice 
Intraveno
us  
Non cytotoxic  
Higher 
analgesia 
than negative 
[113] 
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cells controls 
PLGA NPs 
surface 
modified with 
octa-arginine 
Loperami
de 
Cell viability 
assay in 
Caco cells 
Antinocice
ptive 
testing in 
mice 
Intranasa
l 
and 
intraveno
us  
No toxic at 
tested 
concentration
s 
Highest rate 
and extent of 
drug delivery 
[114] 
Polysorbate-
80-coated 
poly(Butylcyan
oacrylate) 
nanoparticles 
Dalarguin 
Transendot
helial 
permeabilit
y studies in 
an in vitro 
blood-brain 
barrier 
model 
Antinocice
ptive 
testing in 
mice 
Intraveno
us 
 
A significant 
analgesic 
effect was 
produced by 
drug 
delivered to 
the CNS from 
formulated 
NPs 
[115] 
Chitosan 
nanoparticles 
Delta 
opioid 
peptide 
(DADLE) 
B50 rat 
neuronal 
cells 
- - 
Prolonged 
intracellular 
effects of 
DADLE 
[116] 
Polysorbate 80 
coated 
chitosan 
nanoparticles 
Tapentad
ol 
- 
Pharmacod
ynamic 
studies in 
Wistar rats 
model of 
acute pain: 
Antinocice
ptive test 
Intraveno
us  
Central 
antinociceptiv
e activity 
over a period 
of 24 h 
[117] 
       
Polymeric 
Nanogels 
     
 
 NSAIDs      
Ternary 
chitosan–
ibuprofen–
gellan nanogel 
Ibuprofen - 
Ex vivo pig 
skin 
permeation 
and pig 
skin 
- 
Enhanced 
permeability 
[118] 
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retention 
studies 
Hydrogels 
containing 
pranoprofen-
loaded PLGA 
nanoparticles 
Pranoprof
en 
- 
Ex vivo skin 
human 
permeation 
and in vivo 
anti-
inflammato
ry efficacy 
studies in 
mice 
Draize 
irritation 
test in 
rabbits 
Topical  
No signs of 
skin irritancy  
One of the 
optimized 
semi-solid 
formulation 
prolonged 
drug contact 
on the skin 
and improved 
its skin 
retention, 
being more 
effective  
[119] 
PNIPAM 
nanogels 
Bupivacai
ne 
Cytotoxicity 
assays in 
different 
cell lines 
Histological 
analysis to 
assay in 
vivo 
nanogels 
biocompati
bility 
Peritonea
l  
Minimal 
cytotoxicity 
to multiple 
cell types 
Well 
tolerated in 
vivo 
[121] 
Poly(e-
caprolactone)– 
poly(ethylene 
glycol)–poly(e-
caprolactone) 
nanoparticles 
in Pluronic F-
127 hydrogel 
Lidocaine - 
Antinocice
ptive 
testing in 
rats 
Subcutan
eous 
 
Prolonged 
duration of 
anesthesia 
and long-
lasting 
sensory 
blockade 
Non systemic 
toxicity or 
skin 
irritation/da
mage  
[122] 
Chitosan 
thermogels 
Ropivacai
ne and 
dexameth
asone 
- 
Neurobeha
vioral 
monitoring 
in rats: 
sensory 
Direct 
applicati
on to the 
sciatic 
Extended 
neural 
blockade 
activity with 
gel system 
[123] 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
and motor 
blockade 
nerve composed of 
chitosan, 
ropivacaine 
and 
dexamethaso
ne 
Thermosensitiv
e gel including 
Ketorolac 
tromethamine 
loaded 
Eudragit® 
RL100 
nanodispersion
s 
Ketorolac 
trometha
mine 
- 
Ex vivo 
transcorne
al 
permeation 
on excised 
bovine 
cornea and 
in vivo 
pharmacok
inetic study 
in rabbits 
Ophthal
mic  
Improved 
corneal drug 
permeation  
High relative 
ocular 
availability 
 
[124] 
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Table 6. Dendrimers and dendritic polymers for pain management described in the 
literature. 
Nanoparticle 
Type 
Drug 
In vitro 
evaluatio
n 
 
In vivo 
evaluation 
 
Administratio
n Route 
Outcomes 
Refere
nce 
Dendrimers       
 NSAIDs      
Adamantane 
based 
dendrons 
Ibuprofen 
Cytotoxici
ty 
evaluation 
in murine 
RAW 
264.7 
macropha
ges 
Anti-
inflammat
ory 
activity 
- - 
The 
coupling 
of 
ibuprofen 
to a 
dendritic 
structure 
increased 
its 
cytotoxicit
y 
Enhanced 
anti-
inflammat
ory 
activity of 
the drug 
[125] 
Polyamidoami
ne 
dendrimers 
Ketoprofe
n 
-           -            - 
Enhanced 
drug 
solubility 
      
[126] 
Polyamidoami
ne 
dendrimers 
Indometh
acin 
In vitro 
skin 
permeatio
n studies 
in rat 
dorsal 
skin 
In vivo 
transdermal 
permeation 
evaluation 
Pharmacokinetic 
study and 
pharmacodyna
mic evaluation 
in carrageenan-
induced rat paw 
Transdermal 
patches 
Increased 
drug  flux 
across the 
skin in 
vitro as 
well as in 
vivo 
[128] 
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edema model 
Triazine based 
dendrimers 
Ketoprofe
n 
- - - 
Enhanced 
drug 
solubility 
[129] 
Polypropylen
e 
oxide cored 
PAMAM 
dendrimers 
Ketoprofe
n, 
Ibuprofen 
and 
Diflunisal 
- 
- 
 
- 
Dendrime
rs are 
highly 
effective 
solubility 
enhancer 
for 
NSAIDs 
[130] 
Cationic 
carbosilane 
dendrimers 
Ibuprofen 
 
Viability 
assay and 
inflammat
ory 
response 
analysis in 
macropha
ges 
- - 
One 
formulati
on 
reduced 
inflammat
ory 
responses 
in a better 
way than 
that 
achieved 
by the 
free drug 
[131] 
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Table 7. Micelles used for pain management described in the literature. 
Nanoparticle 
Type 
Drug 
In vitro 
evaluation 
 
In vivo 
evaluation 
 
Administra
tion Route 
Outcomes 
Refere
nce 
Micelles       
 
Local 
anestheti
c 
     
Polyethylene 
oxide and 
polypropylen
e oxide 
micelles  
Lidocaine 
and 
prilocaine 
- - - 
Suitable 
gelation 
temperatur
e, good 
release 
profile and 
excellent 
long-term 
stability of 
micellar 
formulation 
[133] 
Thermorespo
nsive Mixed 
Micellar 
Nanogel 
Lidocaine 
and 
prilocaine 
Ex Vivo 
permeation 
and 
retention 
studies on 
mice excised 
abdominal 
skin 
Pharmacody
namic 
evaluation  
- - 
Enhanced 
intensity of 
anaesthetic 
effect in an 
invivo 
rabbit 
model  and 
mice tail 
flick model  
Well 
tolerated 
formulation
s by skin 
[134] 
PL407-PL188 
mixed 
micelles 
hydrogels 
Ropivacai
ne 
In vitro 
citotoxicity 
assays in 
3T3-
fibroblasts 
cells 
In vivo local 
toxicity and 
pharmacolo
gical 
evaluation 
in rats 
- 
Reduced 
cytotoxic 
effects 
No 
inflammati
on signs  
[135] 
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Increased 
analgesic 
effects for 
the micellar 
formulation 
 
mPEG-
PLA/Solutol® 
HS15 mixed 
micelles 
Propofol 
Stability of 
mixed 
micelles 
under 
storage 
condition 
Sleep/recov
ery studies 
in rats 
Intravenou
s route 
(caudal 
vein) 
Drug-
loaded 
micelles 
were stable 
at room 
temperatur
e 
Pharmacolo
gical 
effect of 
mixed 
micelles 
was 
comparable 
to 
commercial 
lipidic 
emulsions 
[136] 
 NSAIDs      
Micellar 
solutions 
composed of 
single, 
binary, and 
ternary 
surfactant 
systems 
Naproxen - 
- 
 
- 
Solubilizati
on capacity 
of mixed 
surfactant 
systems 
was better 
than those 
of single-
surfactant  
Cationic 
surfactants 
exhibited 
higher 
solubilizatio
n capacity 
[137] 
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than 
nonionics 
and 
anionics 
Pluronic 
L81/P123 
mixed 
micelles 
Aceclofen
ac 
 
- - - 
High drug 
entrapment 
efficiency, 
sustained 
release 
profile and 
good 
stability 
[138] 
Poly(ethylen
e oxide)-
Poly(β-benzyl 
L-aspartate) 
Block 
Copolymer 
Micelles 
Indometh
acin 
- - - 
Drug 
delivery  
controlled 
by the 
medium pH 
and 
interaction 
between 
drug and 
the 
hydrophobi
c core of 
the micelles 
[139] 
Complex 
Micelles 
Ibuprofen - - - 
Drug 
release rate 
could be 
controlled 
by 
modifying 
the size and 
permeabilit
y of the 
channels  
[140] 
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Table 8. Niosomes used for pain management described in the literature. 
Nanoparticle 
Type 
Drug 
In vitro 
evaluati
on 
 
In vivo 
evaluation 
 
Administr
ation 
Route 
Outcomes 
Refere
nce 
Niosomes       
 
Local 
anesthetic 
     
Neutrally, 
positively and 
negatively 
charged 
Tween20/Chol
esterol 
vesicles 
Lidocaine or 
lidocaine 
hydrochlori
de 
Diffusion 
experim
ents in 
abdomin
al skin of 
male 
nude 
mice 
- - 
Drug 
permeation 
rate was 
quite similar 
for niosomes 
and 
liposomes A 
higher 
permeation 
flux and a 
shorter lag 
time of 
niosomes 
with respect 
to classical 
liposomes 
[141] 
Polysorbate-
20 derivatized 
by glycine 
niosomes 
Lidocaine 
Cytotoxi
city 
studies 
in 
immorta
lized 
HaCaT 
cells and 
immorta
lized 
mouse 
fibroblas
ts 
Balb/3T3  
In vivo 
efficacy 
study of the 
drug-loaded 
niosomes in 
murine pain 
and 
inflammatio
n models 
Subcutane
ous  
Not 
cytotoxic. 
Enhanced 
therapeutic 
effects of 
optimized 
formulations 
in in vivo 
pain and 
inflammatio
n models 
[142] 
 NSAIDs      
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Polysorbate-
20 derivatized 
by glycine 
niosomes 
Ibuprofen 
Cytotoxi
city 
studies 
in 
immorta
lized 
HaCaT 
cells and 
immorta
lized 
mouse 
fibroblas
ts 
In vivo 
efficacy 
study of the 
drug-loaded 
niosomes in 
murine pain 
and 
inflammatio
n 
 
 
Subcutane
ous  
Not 
cytotoxic 
Enhanced 
therapeutic 
effects of 
optimized 
formulations 
in in vivo 
pain and 
inflammatio
n models 
[142] 
Span 60/F127 
and Tween 
60/F127 
niosomes 
Diclofenac 
sodium 
- 
Ex vivo 
permeation 
studies in 
rabbit ear 
skin 
- 
Higher drug 
flux through 
ear 
membrane 
after its 
nanoencaps
ulation 
[143] 
Phosphatidylc
holine (PC): 
Cholestherol 
(CH), PC:CH: 
stearylamine 
or PC:CH: 
dicetylphosph
ate niosomes 
Aceclofenac - 
Anti-
inflammator
y activity in 
rat paw 
oedema 
model 
 
Topical  
Prolonged 
anti-
inflammator
y effect 
[144] 
       
Niosomal 
hydrogels 
      
 NSAIDs      
Niosomal gel Lornoxicam 
In vitro 
skin 
permeati
on 
studies 
in rat 
skin 
Anti-
inflammator
y effects of 
the 
prepared 
niosomal 
gels in rat 
inflammator
y model and 
Topical  
Enhanced 
anti-
inflammator
y effect of 
drug 
niosomal gel 
No signs of 
[145] 
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skin 
irritation 
test 
irritation  
Niosomal 
hydrogels 
Meloxicam 
In vitro 
skin 
permeati
on 
studies 
in rat 
skin 
Anti-
inflammator
y effects of 
the 
prepared 
niosomal 
gels in rat 
inflammator
y model 
Topical  
All niosomal 
gel 
formulations 
had 
significant 
anti-
inflammator
y effect 
[146] 
Niosomal Gel Lornoxicam 
In vitro 
occlusivi
ty study 
Primary skin 
irritation 
study in 
rabbits and  
pharmacody
namic 
evaluation 
using  
rat paw 
edema 
model 
Topical  
No signs of 
irritation.  
Higher 
occlusivity 
properties 
Improved 
anti-
inflammator
y activity of 
drug after its 
encapsulatio
n in 
niosomal 
system. 
[147] 
Vesicular 
hydrogel 
Meloxicam - 
Acute anti-
inflammator
y activity 
analysis of 
hydrogels in 
rat paw 
edema 
model 
Topical  
Anti-
inflammator
y activity 
enhancemen
t of 
meloxicam 
 
[148] 
Elastic and 
conventional 
Tween 61 
niosomes  
incorporated 
into a 
Diclofenac 
diethylamm
onium 
In vitro 
skin 
permeati
on study 
in rat 
skin 
In vivo anti-
inflammator
y assay in 
rat ear 
edema 
model 
Topical  
High fluxes 
of drug 
entrapped in 
niosomes 
through rat 
skin and high 
[149] 
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Carbopol gel  
 
anti-
inflammator
y activity of 
formulations 
in rat ear 
edema assay 
Tween20:chol
esterol 
Niosomal gel 
formulation 
Nimesulide 
In vitro 
skin 
permeati
on study 
in 
human 
cadaver 
skin 
In vivo anti-
inflammator
y assay in 
rat paw 
edema 
model 
Topical  
Higher drug 
retention 
and 
increased 
permeation 
across the 
skin after 
niosomal 
drug 
encapsulatio
n 
Prolonged 
and 
enhanced 
anti-
inflammator
y activity 
[150] 
Span 
60:cholesterol 
Niosomal gel 
formulations 
Aceclofenac 
In vitro 
rat skin 
permeati
on study 
In vivo anti-
inflammator
y activity 
effects of 
niosomal 
gels in rat 
paw edema 
model 
Topical  
Improved 
anti-
inflammator
y activity of 
niosomal gel 
formulations 
[151] 
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Table 9. Inorganic nanoparticles used in pain management described in the literature. 
Nanoparticl
e Type 
Drug 
In vitro 
evaluat
ion 
 
In vivo 
evaluation 
 
Administr
ation 
Route 
Outcomes 
Refere
nce 
Silica 
mesoporou
s materials 
      
 NSAIDs      
SBA-15 Ketoprofen - 
The analgesic 
and anti-
inflammatory 
activity studies 
in carrageenan-
induced edema 
in paw rat 
model 
Oral  
Enhanced 
drug 
bioavailabi
lity after 
encapsulat
ion  
[152] 
MCM-41 Piroxicam - - - 
Good 
matrix to 
prepare a 
rapid 
onset 
therapeuti
c 
formulatio
n with 
poorly 
water-
soluble 
drug 
[153] 
MCM-41 Ibuprofen - - - 
Drug was 
homogeno
usly 
loaded 
into MCM-
41 without 
adversely 
affecting 
its activity  
[154] 
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SBA-15 Indomethacin - - - 
Enhanced 
dissolution 
of  poorly 
soluble 
drugs after 
encapsulat
ion in SBA-
15 
[155] 
SBA-15 Indomethacin - - - 
Immediate 
and 
complete 
drug 
release 
from SBA-
15 
happened 
in 
simulated 
intestinal 
fluid  
[156] 
 Others      
MCM-41 
Δ9- 
tetrahydrocan
nabinol and 
ARA29 
Cell 
viabilit
y 
studies 
in 
murine 
brain 
microgl
ia cells 
Thermal 
hyperalgesia 
and mechanical 
allodynia 
evaluation in 
chronic 
constriction 
injury mice 
model 
Intraperito
neal  
Attenuatio
n of in 
vitro and 
in vivo 
inflammati
on and a 
sustained 
relief of 
neuropath
ic pain in 
injured 
animals 
[157] 
       
Magnetic 
nanoparticl
es 
      
 NSAIDs      
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Magnetic 
nanocarrier
s 
functionaliz
ed with 
oleic acid 
and/or 
chitosan 
Diclofenac 
sodium 
- - - 
Controlled 
drug 
release 
from novel 
magnetic 
nanocarrie
r 
[158] 
Fe/ethylcell
ulose 
(core/shell) 
nanoparticl
es 
Diclofenac 
sodium 
- - - 
High 
drug 
loading, 
enhanced 
magnetic 
susceptibil
ity and 
prolonged 
drug 
release 
[159] 
 
Local 
anesthetic 
     
Magnetic 
nanoparticl
es 
nanocompl
exes 
Ropivacaine - 
Assessment of 
ankle block and 
pharmacokineti
cs experiments 
in rats 
Intraveno
us  
Ankle 
block after 
injection 
of 
nanocomp
lexes and 
magnet 
applicatio
n at the 
ankle 
[160] 
Magnetic 
Nanogel  
Bupivacaine - 
Assessment of 
ankle block and 
paw withdrawal 
latency testing 
Intraveno
us  
Ankle 
block after 
injection 
of 
nanocomp
lexes and 
magnet 
applicatio
n at the 
[161] 
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ankle 
Fe3O4 NPs 
 
- - 
Mechanical and 
thermal 
response 
analysis in 
 mice chronic 
inflammatory 
pain model and 
immunohistoch
emistry analysis 
in paw skin 
sections 
Injection 
into the 
paw 
Dose-
dependent 
analgesic 
effect  
[162] 
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Figure 1. (A) Pain classification. (B) Pathophysiological classification of pain. 
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Figure 2. Recommended multimodal pain management. 
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Figure 3. Organic and inorganic nanoparticulated formulations as drug delivery systems 
for pain treatment. 
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